|
US6765087B1
(en)
*
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
DE69427974T2
(de)
*
|
1993-04-29 |
2001-12-06 |
Unilever N.V., Rotterdam |
Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
|
|
EP0739981A1
(en)
*
|
1995-04-25 |
1996-10-30 |
Vrije Universiteit Brussel |
Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
|
|
US20040248201A1
(en)
*
|
1996-06-27 |
2004-12-09 |
Serge Muyldermans |
Recognition molecules interacting specifically with the active site or cleft of a target molecule
|
|
CA2258518C
(en)
*
|
1996-06-27 |
2011-11-22 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Recognition molecules interacting specifically with the active site or cleft of a target molecule
|
|
US6454946B1
(en)
*
|
1996-10-10 |
2002-09-24 |
Neose Technologies, Inc. |
Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration
|
|
US20030228310A1
(en)
*
|
1996-12-23 |
2003-12-11 |
Advanced Biotherapy, Inc. |
Treatment of skin diseases
|
|
BR9907241A
(pt)
*
|
1998-01-26 |
2000-10-17 |
Unilever Nv |
Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
|
|
JP2002512776A
(ja)
*
|
1998-04-28 |
2002-05-08 |
スミスクライン・ビーチャム・コーポレイション |
免疫原性の低下したモノクローナル抗体
|
|
CN1252264C
(zh)
|
1999-04-22 |
2006-04-19 |
荷兰联合利华有限公司 |
利用单价抗原－结合蛋白抑制病毒感染
|
|
US6924359B1
(en)
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
|
EP1196532A1
(en)
|
1999-07-27 |
2002-04-17 |
Unilever N.V. |
Bleaching detergent compositions
|
|
EP1212100B1
(en)
*
|
1999-09-16 |
2005-04-06 |
Unilever Plc |
Delivery system for antidandruff agent
|
|
EP1088892A1
(en)
*
|
1999-09-24 |
2001-04-04 |
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. |
Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
|
|
US6479280B1
(en)
|
1999-09-24 |
2002-11-12 |
Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw |
Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
|
|
EP1242460B1
(en)
|
1999-11-29 |
2006-10-18 |
Unilever Plc |
Immobilisation of proteins using a polypeptide segment
|
|
EP1118669A3
(en)
*
|
1999-12-17 |
2001-08-29 |
Unilever Plc |
Production of camelid antibodies in plants
|
|
ATE428733T1
(de)
|
2000-03-14 |
2009-05-15 |
Unilever Nv |
Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
|
|
US6696620B2
(en)
|
2000-05-02 |
2004-02-24 |
Epicyte Pharmaceutical, Inc. |
Immunoglobulin binding protein arrays in eukaryotic cells
|
|
EP1328626B1
(en)
|
2000-05-26 |
2013-04-17 |
National Research Council Of Canada |
Single-domain brain-targeting antibody fragments derived from llama antibodies
|
|
AU2001268855A1
(en)
|
2000-05-26 |
2001-12-03 |
National Research Council Of Canada |
Single-domain antigen-binding antibody fragments derived from llama antibodies
|
|
US20050196755A1
(en)
*
|
2000-11-17 |
2005-09-08 |
Maurice Zauderer |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
|
DE60126130T2
(de)
*
|
2000-11-17 |
2007-10-18 |
The University Of Rochester |
In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
|
|
US20060064782A1
(en)
*
|
2000-12-18 |
2006-03-23 |
Conopco, Inc. |
Production of antibodies
|
|
CA2431485A1
(en)
|
2000-12-19 |
2002-06-27 |
Unilever Plc |
Stabilization of antibodies or fragments thereof
|
|
ATE519783T1
(de)
*
|
2000-12-22 |
2011-08-15 |
Grad Carole Legal Representative Of Kaplan Howard |
ßPHAGE DISPLAYß BIBLIOTHEKE VON MENSCHLICHEN VH FRAGMENTEN
|
|
AU2002305914A1
(en)
|
2001-01-12 |
2002-10-21 |
Chiron Corporation |
Nucleic acid mucosal immunization
|
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20050069538A1
(en)
*
|
2003-09-18 |
2005-03-31 |
Gregorio Aversa |
Therapeutic binding molecules
|
|
US20040058445A1
(en)
*
|
2001-04-26 |
2004-03-25 |
Ledbetter Jeffrey Alan |
Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
|
|
US20040062768A1
(en)
*
|
2001-06-05 |
2004-04-01 |
Advanced Biotherapy, Inc. |
Compositions and methods for treating hyperimmune response in the eye
|
|
US20050152902A1
(en)
*
|
2001-06-05 |
2005-07-14 |
Advanced Biotherapy, Inc. |
Treatment of diabetic retinopathy
|
|
US20040086508A1
(en)
*
|
2001-06-05 |
2004-05-06 |
Advanced Biotherapy, Inc. |
Treatment of organ transplant rejection
|
|
US6861056B2
(en)
*
|
2001-06-05 |
2005-03-01 |
Advanced Biotherapy, Inc. |
Compositions and methods for treating hyperimmune response in the eye
|
|
JP2005289809A
(ja)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
|
AU2002360068B2
(en)
*
|
2001-12-21 |
2009-09-03 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Method for cloning of variable domain sequences
|
|
CA2471645A1
(en)
*
|
2002-01-03 |
2003-07-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Immunoconjugates useful for treatment of tumours
|
|
CA2472927A1
(en)
|
2002-01-10 |
2003-07-17 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
A novel splice variant of myd88 and uses thereof
|
|
WO2003068977A2
(de)
|
2002-02-10 |
2003-08-21 |
Apoxis Sa |
Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
|
|
US20030219436A1
(en)
*
|
2002-03-15 |
2003-11-27 |
Ledbetter Jeffrey A. |
Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
|
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
|
DK1517921T3
(da)
*
|
2002-06-28 |
2006-10-09 |
Domantis Ltd |
Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
|
|
EP2269656B1
(en)
|
2002-07-15 |
2014-08-20 |
Board Of Regents, The University Of Texas |
Selected antibodies binding to aminophospholipids and their use in treatment, such as cancer
|
|
ATE512364T1
(de)
|
2002-08-07 |
2011-06-15 |
Ablynx Nv |
Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
|
|
US7425619B2
(en)
|
2002-08-14 |
2008-09-16 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
GB0219720D0
(en)
*
|
2002-08-23 |
2002-10-02 |
Univ Aberdeen |
Polypeptide
|
|
US20040052790A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Advanced Biotherapy, Inc. |
Treatment of schizophrenia
|
|
US20060034845A1
(en)
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
|
CA2505325C
(en)
|
2002-11-08 |
2014-02-25 |
Ablynx N.V. |
Stabilized single domain antibodies
|
|
AU2003286002B2
(en)
|
2002-11-08 |
2011-06-16 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
|
GB0230203D0
(en)
*
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
|
KR20050092029A
(ko)
|
2003-01-10 |
2005-09-16 |
아블린쓰 엔.브이. |
폰 빌레브란트 인자(ｖＷＦ) 또는 콜라겐에 대한낙타과로부터의 재조합 ＶＨＨ 단일 도메인 항체
|
|
EP1437764A1
(en)
*
|
2003-01-10 |
2004-07-14 |
S.O.I. Tec Silicon on Insulator Technologies S.A. |
A compliant substrate for a heteroepitaxy, a heteroepitaxial structure and a method for fabricating a compliant substrate
|
|
CA2521826C
(en)
|
2003-04-11 |
2013-08-06 |
Jennifer L. Reed |
Recombinant il-9 antibodies and uses thereof
|
|
EP2221317A3
(en)
|
2003-06-30 |
2011-07-27 |
Domantis Limited |
PEGylated single domain antibodies (dAb)
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
EP3095793B1
(en)
|
2003-07-28 |
2020-03-25 |
Genentech, Inc. |
Reducing protein a leaching during protein a affinity chromatography
|
|
JP2007511738A
(ja)
|
2003-08-08 |
2007-05-10 |
ジーンニュース インコーポレーテッド |
変形性関節症のバイオマーカー及びその使用
|
|
WO2005081687A2
(en)
*
|
2003-09-30 |
2005-09-09 |
Centocor, Inc. |
Human hinge core mimetibodies, compositions, methods and uses
|
|
JP2007513072A
(ja)
|
2003-11-05 |
2007-05-24 |
パリンゲン インコーポレーテッド |
Ｃｄｉｍ結合抗体における増強されたｂ細胞細胞傷害性
|
|
AU2003283136A1
(en)
|
2003-11-07 |
2005-05-26 |
Ablynx N.V. |
Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
|
|
US7999071B2
(en)
*
|
2003-12-12 |
2011-08-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-1
|
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
|
WO2005105984A2
(en)
*
|
2004-04-12 |
2005-11-10 |
The Trustees Of The University Of Pennsylvania |
Culture conditions and growth factors affecting fate determination, self-renewal and expansion of mouse spermatogonial stem cells
|
|
JP2008501337A
(ja)
*
|
2004-06-04 |
2008-01-24 |
ジェネンコー・インターナショナル・インク |
抗体重鎖を用いたスクリーニング法
|
|
US20050276806A1
(en)
*
|
2004-06-15 |
2005-12-15 |
Advanced Biotherapy, Inc. |
Treatment of autism
|
|
US20050276807A1
(en)
*
|
2004-06-15 |
2005-12-15 |
Advanced Biotherapy, Inc. |
Treatment of acne
|
|
ES2440990T5
(es)
|
2004-07-22 |
2022-10-25 |
Univ Erasmus Med Ct Rotterdam |
Moléculas de unión
|
|
GB2416768A
(en)
*
|
2004-07-22 |
2006-02-08 |
Univ Erasmus |
Heavy chain immunoglobulin complexes
|
|
US20060177445A1
(en)
*
|
2004-08-16 |
2006-08-10 |
Boris Skurkovich |
Treatment of inflammatory skin diseases
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
RU2401842C2
(ru)
|
2004-10-08 |
2010-10-20 |
Домантис Лимитед |
Антагонисты и способы их применения
|
|
WO2006044263A2
(en)
|
2004-10-12 |
2006-04-27 |
Advanced Biotherapy, Inc. |
Treatment of herpes
|
|
CA2583017A1
(en)
*
|
2004-10-13 |
2006-04-20 |
Ablynx N.V. |
Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
|
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
AU2006205900B8
(en)
|
2005-01-14 |
2012-04-05 |
Ablynx N.V. |
Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets
|
|
EP1844073A1
(en)
*
|
2005-01-31 |
2007-10-17 |
Ablynx N.V. |
Method for generating variable domain sequences of heavy chain antibodies
|
|
WO2006086242A2
(en)
|
2005-02-07 |
2006-08-17 |
Genenews, Inc. |
Mild osteoarthritis biomarkers and uses thereof
|
|
WO2006086667A2
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
|
DE602006021552D1
(de)
|
2005-03-11 |
2011-06-09 |
Syngenta Ltd |
Bekämpfung von schädlichen nagetieren
|
|
JP5628476B2
(ja)
|
2005-04-28 |
2014-11-19 |
ベンタナ・メデイカル・システムズ・インコーポレーテツド |
抗体コンジュゲート
|
|
EP1893241A2
(en)
*
|
2005-04-28 |
2008-03-05 |
Ventana Medical Systems, Inc. |
Fluorescent nanoparticles conjugated to antibodies via a peg linker
|
|
SI1888640T1
(sl)
|
2005-05-18 |
2012-07-31 |
Ablynx Nv |
Izboljšana nanotelesa proti faktorju nekroze tumorja alfa
|
|
LT2444424T
(lt)
|
2005-05-20 |
2018-10-25 |
Ablynx N.V. |
Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
|
|
DE102005023617A1
(de)
|
2005-05-21 |
2006-11-23 |
Aspre Ag |
Verfahren zum Mischen von Farben in einem Display
|
|
CN105012953B
(zh)
*
|
2005-07-25 |
2018-06-22 |
阿普泰沃研发有限责任公司 |
用cd37-特异性和cd20-特异性结合分子减少b-细胞
|
|
SG10201402712QA
(en)
|
2005-08-31 |
2014-08-28 |
Merck Sharp & Dohme |
Engineered anti-il-23 antibodies
|
|
JP2009507023A
(ja)
|
2005-09-01 |
2009-02-19 |
シェーリング コーポレイション |
自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
|
|
US20090233357A1
(en)
*
|
2005-09-27 |
2009-09-17 |
Abedelnasser Abulrob |
Targeted Delivery of Compounds Using Multimerization Technology
|
|
WO2007041171A2
(en)
*
|
2005-09-29 |
2007-04-12 |
Medimmune, Inc. |
Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
|
|
US7526409B2
(en)
*
|
2005-10-07 |
2009-04-28 |
Oracle International Corporation |
Automatic performance statistical comparison between two periods
|
|
GB0521139D0
(en)
|
2005-10-18 |
2005-11-23 |
Univ Sheffield |
Therapeutic agent
|
|
US8249814B2
(en)
|
2005-10-21 |
2012-08-21 |
Genenews Inc. |
Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject
|
|
GB0522460D0
(en)
*
|
2005-11-03 |
2005-12-14 |
Prendergast Patrick T |
Composition and method for the treatment of avian influenza
|
|
CA2631005C
(en)
*
|
2005-11-23 |
2017-02-28 |
Ventana Medical Systems, Inc. |
Molecular conjugate
|
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
|
WO2007082899A1
(en)
|
2006-01-17 |
2007-07-26 |
Vib Vzw |
Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
|
|
US20100047171A1
(en)
*
|
2006-01-24 |
2010-02-25 |
Roland Beckmann |
Fusion Proteins That Contain Natural Junctions
|
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
|
|
US7504106B2
(en)
*
|
2006-03-14 |
2009-03-17 |
Boris Skurkovich |
Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
|
|
WO2007110219A1
(en)
*
|
2006-03-27 |
2007-10-04 |
Ablynx N.V. |
Medical delivery device for therapeutic proteins based on single domain antibodies
|
|
BRPI0710637A2
(pt)
*
|
2006-04-21 |
2012-03-13 |
Wyeth |
análise do perfil de expressão diferencial de fenótipos de cultura celular e seus usos
|
|
US20090074734A1
(en)
|
2006-05-02 |
2009-03-19 |
Actogenix N.V. |
Microbial intestinal delivery of obesity related peptides
|
|
KR101571027B1
(ko)
|
2006-06-12 |
2015-11-23 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
효과기 기능을 갖는 단일쇄 다가 결합 단백질
|
|
JP2009544761A
(ja)
|
2006-06-14 |
2009-12-17 |
マクロジェニクス，インコーポレーテッド |
低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
|
|
US8785599B2
(en)
|
2006-06-26 |
2014-07-22 |
Macrogenics, Inc. |
FcγRIIB—specific antibodies and methods of use thereof
|
|
US8129145B2
(en)
|
2006-07-13 |
2012-03-06 |
Wyeth Llc |
Production of glycoproteins
|
|
PL2292663T3
(pl)
|
2006-08-28 |
2014-03-31 |
Kyowa Hakko Kirin Co Ltd |
Antagonistyczne ludzkie przeciwciała monoklonalne swoiste wobec ludzkiego LIGHT
|
|
PL3028716T3
(pl)
|
2006-10-10 |
2021-03-08 |
Regenesance B.V. |
Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
|
|
GB0621513D0
(en)
|
2006-10-30 |
2006-12-06 |
Domantis Ltd |
Novel polypeptides and uses thereof
|
|
ES2905054T3
(es)
|
2006-11-01 |
2022-04-06 |
Ventana Med Syst Inc |
Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
|
|
CA2672201A1
(en)
|
2006-11-07 |
2008-05-15 |
Vib Vzw |
Use of myb gene to diagnose and treat t-cell acute lumphoblastic leukemia
|
|
US8470332B2
(en)
|
2006-11-22 |
2013-06-25 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
|
AU2007328900A1
(en)
*
|
2006-12-05 |
2008-06-12 |
Ablynx N.V. |
Peptides capable of binding to serum proteins
|
|
CA2671538A1
(en)
|
2006-12-14 |
2008-06-26 |
Leonard G. Presta |
Engineered anti-tslp antibody
|
|
AU2007336242B2
(en)
|
2006-12-19 |
2012-08-30 |
Ablynx N.V. |
Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
|
AU2007336243B2
(en)
|
2006-12-19 |
2012-07-26 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
|
|
US9023352B2
(en)
|
2007-02-20 |
2015-05-05 |
Tufts University |
Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
|
|
EP2121757A2
(en)
*
|
2007-02-21 |
2009-11-25 |
Ablynx N.V. |
Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
|
|
JP2010518858A
(ja)
|
2007-02-23 |
2010-06-03 |
シェーリング コーポレイション |
操作された抗−ｉｌ−２３ｐ１９抗体
|
|
RS58098B1
(sr)
|
2007-02-23 |
2019-02-28 |
Merck Sharp & Dohme |
Anti-il-23p19 antitela proizvedena genetičkim inženjerstvom
|
|
CA2679381A1
(en)
|
2007-02-28 |
2008-09-04 |
Schering Corporation |
Engineered anti-il-23r antibodies
|
|
EP2417974A1
(en)
|
2007-02-28 |
2012-02-15 |
Schering Corporation |
Combination therapy for treatment of immune disorders
|
|
EP2924113B1
(en)
*
|
2007-03-02 |
2019-04-10 |
Wyeth LLC |
Use of copper and glutamate in cell culture for production of polypeptides
|
|
WO2008118013A2
(en)
|
2007-03-23 |
2008-10-02 |
To-Bbb Holding B.V. |
Targeted intracellular delivery of antiviral agents
|
|
TW200902708A
(en)
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
|
AU2008246442B2
(en)
|
2007-05-04 |
2014-07-03 |
Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa |
Engineered rabbit antibody variable domains and uses thereof
|
|
MX2009012341A
(es)
|
2007-05-14 |
2010-02-17 |
Medimmune Llc |
Metodos para reducir niveles de eosinofilos.
|
|
DK2167963T3
(da)
|
2007-05-23 |
2019-06-24 |
Ventana Med Syst Inc |
Polymerbærere til immunhistokemi og in situ-hybridisering
|
|
US8703485B2
(en)
|
2007-06-01 |
2014-04-22 |
Omt, Inc. |
Germ cells having inactivated endogenous immunoglobulin genes, and transgenic animals derived therefrom
|
|
WO2008157299A2
(en)
*
|
2007-06-15 |
2008-12-24 |
Wyeth |
Differential expression profiling analysis of cell culture phenotypes and uses thereof
|
|
AU2008270274B2
(en)
|
2007-07-03 |
2012-06-28 |
Ablynx N.V. |
Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
|
|
CA2694737C
(en)
|
2007-07-13 |
2019-05-14 |
Bac Ip B.V. |
Single-domain antigen-binding proteins that bind mammalian igg
|
|
ES2535319T3
(es)
|
2007-07-13 |
2015-05-08 |
Ventana Medical Systems, Inc. |
Anticuerpos específicos para el dominio regulador C-terminal del EGFR y su uso
|
|
EP2188371B1
(en)
|
2007-08-09 |
2017-12-20 |
Wyeth LLC |
Use of perfusion to enhance production of fed-batch cell culture in bioreactors
|
|
CN101842387B
(zh)
|
2007-09-26 |
2014-05-07 |
Ucb医药有限公司 |
双特异性抗体融合物
|
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
|
EP2212432A4
(en)
|
2007-10-22 |
2011-10-19 |
Schering Corp |
COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
|
|
PL2567709T3
(pl)
|
2007-11-02 |
2018-06-29 |
Novartis Ag |
Cząsteczki i sposoby modulowania białka związanego z receptorem dla lipoproteiny o niskiej gęstości 6 (LRP6)
|
|
JP5514399B2
(ja)
*
|
2007-11-02 |
2014-06-04 |
国立大学法人 岡山大学 |
無機硫黄化合物加水分解酵素の製造方法
|
|
JP2011514881A
(ja)
|
2007-11-09 |
2011-05-12 |
ザ ソルク インスティテュート フォー バイオロジカル スタディーズ |
免疫増強剤としてのｔａｍ受容体阻害剤の使用および免疫抑制剤としてのｔａｍ活性化剤の使用
|
|
US8975382B2
(en)
*
|
2007-11-27 |
2015-03-10 |
Ablynx N.V. |
Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
|
|
JP5490714B2
(ja)
|
2007-11-28 |
2014-05-14 |
メディミューン，エルエルシー |
タンパク質製剤
|
|
US20090186358A1
(en)
*
|
2007-12-21 |
2009-07-23 |
Wyeth |
Pathway Analysis of Cell Culture Phenotypes and Uses Thereof
|
|
US8580927B2
(en)
|
2008-01-31 |
2013-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered antibody constant domain molecules
|
|
JP2011525476A
(ja)
|
2008-03-05 |
2011-09-22 |
アブリンクス エン．ヴェー． |
新規の抗原結合二量体複合体、その製造方法及び使用
|
|
ES2447844T3
(es)
|
2008-04-03 |
2014-03-13 |
Vib Vzw |
Anticuerpos de dominio individual capaces de modular la actividad BACE1
|
|
GB0809069D0
(en)
|
2008-05-19 |
2008-06-25 |
Univ Leuven Kath |
Gene signatures
|
|
US9908943B2
(en)
|
2008-04-03 |
2018-03-06 |
Vib Vzw |
Single domain antibodies capable of modulating BACE activity
|
|
JP2011516520A
(ja)
|
2008-04-07 |
2011-05-26 |
アブリンクス エン．ヴェー． |
Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
|
|
MX340204B
(es)
|
2008-04-11 |
2016-06-30 |
Emergent Product Dev Seattle |
Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo.
|
|
EP2268668A1
(en)
|
2008-04-17 |
2011-01-05 |
Ablynx N.V. |
Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
|
|
PT2274331E
(pt)
|
2008-05-02 |
2014-02-27 |
Novartis Ag |
Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações
|
|
CN102099373A
(zh)
|
2008-05-22 |
2011-06-15 |
百时美施贵宝公司 |
基于纤连蛋白的多价支架结构域蛋白
|
|
ES2557594T3
(es)
|
2008-06-05 |
2016-01-27 |
Ventana Medical Systems, Inc. |
Método para el procesamiento histoquímico y el uso de una composición para el procesamiento histoquímico
|
|
GB2461546B
(en)
*
|
2008-07-02 |
2010-07-07 |
Argen X Bv |
Antigen binding polypeptides
|
|
US8444976B2
(en)
|
2008-07-02 |
2013-05-21 |
Argen-X B.V. |
Antigen binding polypeptides
|
|
AR072571A1
(es)
|
2008-07-18 |
2010-09-08 |
Bristol Myers Squibb Co |
Composiciones monovalentes para union a cd28 y procedimientos de uso
|
|
US9034325B2
(en)
|
2008-07-22 |
2015-05-19 |
Ablynx N.V. |
Amino acid sequences directed against multitarget scavenger receptors and polypeptides
|
|
AR072897A1
(es)
|
2008-08-05 |
2010-09-29 |
Novartis Ag |
Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
|
|
WO2010033913A1
(en)
*
|
2008-09-22 |
2010-03-25 |
Icb International, Inc. |
Antibodies, analogs and uses thereof
|
|
US20100136584A1
(en)
*
|
2008-09-22 |
2010-06-03 |
Icb International, Inc. |
Methods for using antibodies and analogs thereof
|
|
CA2739357A1
(en)
|
2008-09-23 |
2010-04-08 |
Wyeth Llc |
Methods for predicting production of activating signals by cross-linked binding proteins
|
|
CN102272154A
(zh)
|
2008-10-29 |
2011-12-07 |
惠氏有限责任公司 |
单域抗原结合性分子的纯化方法
|
|
MX374128B
(es)
|
2008-10-29 |
2025-03-05 |
Ablynx Nv |
Formulaciones de moléculas de unión a antígeno de dominio sencillo.
|
|
MX2011006549A
(es)
|
2008-12-19 |
2011-07-20 |
Schering Corp |
Suplemento alimenticio para el cultivo de celula de mamifero y metodos de uso.
|
|
JP2012512646A
(ja)
|
2008-12-19 |
2012-06-07 |
アブリンクス エン．ヴェー． |
免疫グロブリン配列を生成する方法
|
|
DK2387583T3
(en)
|
2009-01-14 |
2019-01-14 |
Ablynx Nv |
PULMONAL ADMINISTRATION OF VARIABLE IMMUNGLOBULIN SINGLE DOMAINS AND CONSTRUCTIONS THEREOF.
|
|
US20100189919A1
(en)
*
|
2009-01-27 |
2010-07-29 |
Xerox Corporation |
Imaging System And Process Using Monoclonal Antibodies
|
|
US9085795B2
(en)
|
2009-02-04 |
2015-07-21 |
Molecular Innovations, Inc. |
Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
|
|
US10005830B2
(en)
|
2009-03-05 |
2018-06-26 |
Ablynx N.V. |
Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
|
EP2230515B1
(en)
*
|
2009-03-16 |
2014-12-17 |
Agilent Technologies, Inc. |
Passivation of surfaces after ligand coupling
|
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
|
CA2754393C
(en)
|
2009-03-24 |
2015-10-27 |
Wyeth Llc |
Membrane evaporation for generating highly concentrated protein therapeutics
|
|
MX2011010681A
(es)
|
2009-04-10 |
2012-01-20 |
Ablynx Nv |
Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
|
|
EP2424894A1
(en)
|
2009-04-27 |
2012-03-07 |
Novartis AG |
Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
|
|
DK2424895T3
(en)
|
2009-04-27 |
2017-12-18 |
Novartis Ag |
Compositions and Methods for Increasing Muscle Growth
|
|
PL2424889T3
(pl)
|
2009-04-30 |
2016-01-29 |
Ablynx Nv |
Sposób wytwarzania przeciwciał domenowych
|
|
WO2011019423A2
(en)
|
2009-05-20 |
2011-02-17 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
|
DK2438087T3
(en)
|
2009-06-05 |
2017-08-28 |
Ablynx Nv |
TRIVALENT NANOBODY CONSTRUCTIONS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) FOR PREVENTION AND / OR TREATMENT OF AIR INFECTIONS
|
|
JP2012531212A
(ja)
|
2009-07-03 |
2012-12-10 |
アビペップ ピーティーワイ リミテッド |
イムノコンジュゲート及びその作製方法
|
|
DK2451839T3
(da)
|
2009-07-10 |
2020-07-13 |
Ablynx Nv |
Fremgangsmåde til produktion af variable domæner
|
|
SG177763A1
(en)
|
2009-07-28 |
2012-03-29 |
Hoffmann La Roche |
Non-invasive in vivo optical imaging method
|
|
WO2011014438A1
(en)
|
2009-07-31 |
2011-02-03 |
N.V. Organon |
Fully human antibodies to btla
|
|
US9133500B2
(en)
|
2009-08-10 |
2015-09-15 |
MorphoSys A6 |
Screening strategies for the identification of binders
|
|
ES2788869T3
(es)
|
2009-09-03 |
2020-10-23 |
Merck Sharp & Dohme |
Anticuerpos anti-GITR
|
|
FI3725330T3
(fi)
|
2009-09-03 |
2025-11-14 |
Ablynx Nv |
Polypeptidien stabiilit valmisteet ja niiden käyttötarkoitukset
|
|
AU2010290989B2
(en)
|
2009-09-03 |
2016-05-19 |
Cancer Research Technology Limited |
CLEC14A inhibitors
|
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
UY32917A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Moléculas de unión a dll-4
|
|
UY32920A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Moleculas de unión biespecíficas para la terapia anti-angiogénesis
|
|
EP2486056A1
(en)
|
2009-10-09 |
2012-08-15 |
Ablynx N.V. |
Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
|
|
WO2011045079A1
(en)
|
2009-10-15 |
2011-04-21 |
Intercell Ag |
Hepatitis b virus specific human antibodies
|
|
WO2011049449A1
(en)
|
2009-10-22 |
2011-04-28 |
University Of Twente |
Vhh for application in tissue repair, organ regeneration, organ replacement and tissue engineering
|
|
UA108991C2
(uk)
|
2009-10-23 |
2015-07-10 |
Милленниум Фармасьютикалз, Инк. |
Молекула антитіла до gcc і пов'язані композиції та способи лікування раку
|
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
|
WO2011051333A1
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Universal fibronectin type iii bottom-side binding domain libraries
|
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
|
EP2496707B1
(en)
|
2009-11-04 |
2020-02-26 |
Merck Sharp & Dohme Corp. |
Engineered anti-tslp antibody
|
|
US20120282276A1
(en)
|
2009-11-05 |
2012-11-08 |
The Regents Of The University Of Michigan |
Biomarkers predictive of progression of fibrosis
|
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
|
AU2010328046C1
(en)
*
|
2009-12-10 |
2018-01-18 |
Regeneron Pharmaceuticals, Inc. |
Mice that make heavy chain antibodies
|
|
WO2011072266A2
(en)
|
2009-12-11 |
2011-06-16 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating hematopoiesis
|
|
LT3309176T
(lt)
|
2009-12-14 |
2026-01-26 |
Ablynx N.V. |
Imunoglobulino vieno kintamojo domeno antikūnai nuo ox40l, konstruktai ir jų terapinis naudojimas
|
|
WO2011084357A1
(en)
|
2009-12-17 |
2011-07-14 |
Schering Corporation |
Modulation of pilr to treat immune disorders
|
|
WO2011075786A1
(en)
|
2009-12-23 |
2011-06-30 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them 2
|
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
|
TWI513466B
(zh)
|
2010-01-20 |
2015-12-21 |
Boehringer Ingelheim Int |
抗凝血劑解毒劑
|
|
JP2013518853A
(ja)
|
2010-02-05 |
2013-05-23 |
アブリンクス エン．ヴェー． |
血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド
|
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
|
CA2789125A1
(en)
|
2010-02-10 |
2011-08-18 |
Novartis Ag |
Methods and compounds for muscle growth
|
|
WO2011098518A2
(en)
|
2010-02-11 |
2011-08-18 |
Ablynx Nv |
Delivery of immunoglobulin variable domains and constructs thereof
|
|
AU2011214299B2
(en)
|
2010-02-11 |
2014-07-31 |
Ablynx Nv |
Methods and compositions for the preparation of aerosols
|
|
DK2539355T3
(da)
|
2010-02-26 |
2017-01-02 |
Ventana Med Syst Inc |
IN-SITU-hybridisering med polytag-prober
|
|
CN102781962B
(zh)
|
2010-03-03 |
2014-12-10 |
阿布林克斯公司 |
双互补位A-β结合多肽
|
|
EP2552962B1
(en)
|
2010-03-26 |
2016-03-23 |
Ablynx N.V. |
Immunoglobulin single variable domains directed against cxcr7
|
|
US20130041349A1
(en)
|
2010-03-26 |
2013-02-14 |
Westfaelische Wilhelms-Universitaet Muenster |
Substitute therapy for glucocorticoids
|
|
WO2013174537A1
(en)
|
2012-05-24 |
2013-11-28 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
|
US9101674B2
(en)
|
2010-03-29 |
2015-08-11 |
Vib Vzw |
Targeting and in vivo imaging of tumor-associated macrophages
|
|
US9556273B2
(en)
|
2010-03-29 |
2017-01-31 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
|
CN104961827A
(zh)
|
2010-04-06 |
2015-10-07 |
阿格罗塞文公司 |
农用化学品的特异性输送
|
|
GB201105584D0
(en)
|
2011-04-01 |
2011-05-18 |
Imp Innovations Ltd |
Cancer methods
|
|
US20130034853A1
(en)
|
2010-04-20 |
2013-02-07 |
Brian Kelly |
Two-color chromogenic in situ hybridization
|
|
CN103118692A
(zh)
|
2010-04-26 |
2013-05-22 |
Atyr医药公司 |
与半胱氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
|
JP6294074B2
(ja)
|
2010-04-27 |
2018-03-14 |
エータイアー ファーマ， インコーポレイテッド |
イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
US8993723B2
(en)
|
2010-04-28 |
2015-03-31 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
|
|
US9034320B2
(en)
|
2010-04-29 |
2015-05-19 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
|
|
CA2797374C
(en)
|
2010-04-29 |
2021-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
|
|
WO2011137395A1
(en)
|
2010-04-30 |
2011-11-03 |
Rother Russell P |
Anti-c5a antibodies and methods for using the antibodies
|
|
US8961961B2
(en)
|
2010-05-03 |
2015-02-24 |
a Tyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
|
|
JP6008840B2
(ja)
|
2010-05-03 |
2016-10-19 |
エータイアー ファーマ， インコーポレイテッド |
フェニルアラニルαｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
AU2011248230B2
(en)
|
2010-05-03 |
2016-10-06 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
|
|
CA2805267C
(en)
|
2010-05-04 |
2019-07-30 |
The Brigham And Women's Hospital, Inc. |
Detection and treatment of fibrosis
|
|
CN102985103A
(zh)
|
2010-05-04 |
2013-03-20 |
Atyr医药公司 |
与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
|
|
US8877188B2
(en)
|
2010-05-04 |
2014-11-04 |
The Brigham And Women's Hospital, Inc. |
Detection and treatment of non-dermal fibrosis
|
|
JP2013527761A
(ja)
|
2010-05-06 |
2013-07-04 |
ノバルティス アーゲー |
治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）多価抗体の組成物および使用方法
|
|
MX2012012928A
(es)
|
2010-05-06 |
2013-05-01 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
|
|
JP6145404B2
(ja)
|
2010-05-07 |
2017-06-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
エクスビボでの細胞の検出のための診断的方法
|
|
JP6396656B2
(ja)
|
2010-05-14 |
2018-09-26 |
エータイアー ファーマ， インコーポレイテッド |
フェニルアラニルβｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
PH12012502272A1
(en)
|
2010-05-20 |
2017-07-26 |
Ablynx Nv |
Biological materials related to her3
|
|
EP2575856B1
(en)
|
2010-05-27 |
2017-08-16 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
|
|
MX2012014975A
(es)
|
2010-06-22 |
2013-03-12 |
Univ Colorado Regents |
Anticuerpos al fragmento c3d de componente 3 de complemento.
|
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
|
EP2588865A1
(en)
|
2010-07-02 |
2013-05-08 |
Vib Vzw |
The role of fragile x mental retardation gene and protein in cancer metastasis
|
|
CA2800936A1
(en)
|
2010-07-02 |
2012-01-05 |
Ventana Medical Systems, Inc. |
Hapten conjugates for target detection
|
|
AU2011289831C1
(en)
|
2010-07-12 |
2017-06-15 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
|
|
GB201014715D0
(en)
|
2010-09-06 |
2010-10-20 |
Vib Vzw |
Nanobodies stabilizing functional conformational states of GPCRS
|
|
CA2805572A1
(en)
|
2010-07-16 |
2012-01-19 |
Martin Hegen |
Modified single domain antigen binding molecules and uses thereof
|
|
GB201012845D0
(en)
|
2010-07-30 |
2010-09-15 |
Vib Vzw |
Inhibition of dicer function for treatment of cancer
|
|
MY172618A
(en)
|
2010-08-02 |
2019-12-06 |
Regeneron Pharma |
Mice that make binding proteins comprising vl domains
|
|
ES2542615T3
(es)
|
2010-08-16 |
2015-08-07 |
Ventana Medical Systems, Inc. |
Sustratos para detección cromogénica y métodos de uso en los ensayos y kits de detección
|
|
JP2013535981A
(ja)
|
2010-08-20 |
2013-09-19 |
ワイス・エルエルシー |
成長因子不含適合細胞の細胞培養
|
|
CN105037552B
(zh)
|
2010-08-20 |
2019-03-29 |
诺华股份有限公司 |
表皮生长因子受体3（her3)的抗体
|
|
JP5964304B2
(ja)
|
2010-08-25 |
2016-08-03 |
エータイアー ファーマ， インコーポレイテッド |
チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
HUE036251T2
(hu)
|
2010-08-26 |
2018-06-28 |
Agrosavfe N V |
Kitinféle poliszacharid antigént kötõ fehérjék
|
|
US20130224226A1
(en)
|
2010-08-26 |
2013-08-29 |
Agrosavfe N.V. |
Insect binding antibodies
|
|
US20120225081A1
(en)
|
2010-09-03 |
2012-09-06 |
Boehringer Ingelheim International Gmbh |
Vegf-binding molecules
|
|
US20120244141A1
(en)
|
2010-09-28 |
2012-09-27 |
Boehringer Ingelheim International Gmbh |
Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
|
|
WO2012042026A1
(en)
|
2010-09-30 |
2012-04-05 |
Ablynx Nv |
Biological materials related to c-met
|
|
JP2013543384A
(ja)
|
2010-10-05 |
2013-12-05 |
ノバルティス アーゲー |
抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
|
|
ES2660895T3
(es)
|
2010-10-29 |
2018-03-26 |
Ablynx N.V. |
Método para la producción de dominios variables individuales de inmunoglobulina
|
|
GB201018602D0
(en)
|
2010-11-04 |
2010-12-22 |
Vib Vzw |
MMP8 inactivating antigen binding proteins
|
|
EP2635304B1
(en)
|
2010-11-05 |
2017-03-08 |
Morphotek, Inc. |
Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
|
|
CU24111B1
(es)
|
2010-11-08 |
2015-08-27 |
Novartis Ag |
Polipéptidos que se enlazan a cxcr2
|
|
WO2012084895A2
(en)
|
2010-12-20 |
2012-06-28 |
Universiteit Gent |
Crystal structure of flt3 ligand-receptor complex
|
|
US8871442B2
(en)
|
2010-12-30 |
2014-10-28 |
Ventana Medical Systems, Inc. |
Enhanced deposition of chromogens
|
|
US9598499B2
(en)
|
2010-12-30 |
2017-03-21 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Antigen binding formats for use in therapeutic treatments or diagnostic assays
|
|
US9540443B2
(en)
|
2011-01-26 |
2017-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
|
EP3266800B1
(en)
|
2011-02-01 |
2023-11-29 |
Bac Ip B.V. |
Antigen-binding protein directed against epitope in the ch1 domain of human igg antibodies
|
|
AR085141A1
(es)
|
2011-02-03 |
2013-09-11 |
Alexion Pharma Inc |
Un metodo para prolongar la supervivencia de un aloinjerto renal, uso de un anticuerpo anti-cd200 para prolongar la supervivencia de aloinjertos
|
|
JP6385060B2
(ja)
|
2011-03-07 |
2018-09-05 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
治療的に活性な抗体のインビボにおける選択
|
|
EP2683290B1
(en)
|
2011-03-07 |
2018-11-07 |
F.Hoffmann-La Roche Ag |
Methods for in vivo testing of therapeutic antibodies
|
|
CA2825453C
(en)
|
2011-03-14 |
2016-05-10 |
Ventana Medical Systems, Inc. |
A method of analyzing chromosomal translocations and a system therefore
|
|
US9624294B2
(en)
|
2011-03-14 |
2017-04-18 |
Cellmid Limited |
Antibody recognizing N-domain of midkine
|
|
ES2688591T3
(es)
|
2011-03-28 |
2018-11-05 |
Ablynx N.V. |
Método para producir formulaciones sólidas que comprenden dominios variables individuales de inmunoglobulina
|
|
AU2012234284B2
(en)
|
2011-03-28 |
2015-10-08 |
Ablynx Nv |
Bispecific anti-CXCR7 immunoglobulin single variable domains
|
|
PH12013501924A1
(en)
|
2011-03-30 |
2017-10-25 |
Boehringer Ingelheim Int |
Anticoagulant antidotes
|
|
CN103547592A
(zh)
|
2011-03-30 |
2014-01-29 |
埃博灵克斯股份有限公司 |
使用针对TNFα的单结构域抗体治疗免疫病症的方法
|
|
WO2012135408A1
(en)
|
2011-03-31 |
2012-10-04 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
|
|
US9527925B2
(en)
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
|
US20130078247A1
(en)
|
2011-04-01 |
2013-03-28 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to dii4 and ang2
|
|
LT2699264T
(lt)
|
2011-04-20 |
2018-07-10 |
Medimmune, Llc |
Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
EP3590950A1
(en)
|
2011-05-09 |
2020-01-08 |
Ablynx NV |
Method for the production of immunoglobulin single varible domains
|
|
CN107936121B
(zh)
|
2011-05-16 |
2022-01-14 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
|
WO2012163887A1
(en)
|
2011-05-27 |
2012-12-06 |
Ablynx Nv |
Inhibition of bone resorption with rankl binding peptides
|
|
US9580480B2
(en)
|
2011-05-31 |
2017-02-28 |
Massachusetts Institute Of Technology |
Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
|
|
RU2605595C2
(ru)
|
2011-06-13 |
2016-12-20 |
СиЭсЭл Лимитид |
Антитела против g-csfr и их применение
|
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
|
EP3345919A1
(en)
|
2011-06-21 |
2018-07-11 |
VIB vzw |
Binding domains directed against gpcr:g protein complexes and uses derived thereof
|
|
JP2014525736A
(ja)
|
2011-06-23 |
2014-10-02 |
アブリンクス エン．ヴェー． |
ＩｇＥに対する免疫グロブリン単一可変ドメイン
|
|
CN103619878B
(zh)
|
2011-06-23 |
2016-10-26 |
埃博灵克斯股份有限公司 |
结合血清白蛋白的蛋白
|
|
US9365651B2
(en)
|
2011-07-01 |
2016-06-14 |
Novartis Ag |
Method for treating metabolic disorders by administration of an anti-ActRIIB antibody
|
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
|
EP2731970B1
(en)
|
2011-07-15 |
2018-11-28 |
MorphoSys AG |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
|
TW201321405A
(zh)
|
2011-08-17 |
2013-06-01 |
Glaxo Group Ltd |
經修飾之蛋白質及肽
|
|
WO2013033073A1
(en)
|
2011-08-31 |
2013-03-07 |
Ventana Medical Systems, Inc. |
Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration
|
|
GB201115529D0
(en)
|
2011-09-08 |
2011-10-26 |
Imp Innovations Ltd |
Antibodies, uses and methods
|
|
US20150158934A1
(en)
|
2011-09-09 |
2015-06-11 |
Ucl Business Plc |
Broadly neutralizing vhh against hiv-1
|
|
JP5813880B2
(ja)
|
2011-09-19 |
2015-11-17 |
カイマブ・リミテッド |
ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
|
|
US20140235492A1
(en)
|
2011-09-20 |
2014-08-21 |
Institut National De La Sante Et De La Recherche Medicate (Inserm) |
Methods for preparing single domain antibody microarrays
|
|
WO2013041722A1
(en)
|
2011-09-23 |
2013-03-28 |
Ablynx Nv |
Prolonged inhibition of interleukin-6 mediated signaling
|
|
EP2761008A1
(en)
|
2011-09-26 |
2014-08-06 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
EP2747783B1
(en)
|
2011-09-30 |
2017-06-14 |
Ablynx N.V. |
Biological materials related to c-met
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
ES2769786T3
(es)
|
2011-10-14 |
2020-06-29 |
Recordati Ag |
Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
|
|
US9127056B2
(en)
|
2011-10-17 |
2015-09-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
|
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
|
JP2015504413A
(ja)
|
2011-10-28 |
2015-02-12 |
パトリス リミテッド |
Ｐａｔ−ｌｍ１エピトープおよびそれを使用するための方法
|
|
LT2776466T
(lt)
|
2011-11-11 |
2017-11-27 |
Ucb Biopharma Sprl |
Albuminą prisijungiantys antikūnai ir jų prisijungimo fragmentai
|
|
WO2013079606A1
(en)
|
2011-12-01 |
2013-06-06 |
Ventana Medical Systems, Inc. |
Automated dual stain of mirna and protein targets
|
|
US20150147274A1
(en)
|
2011-12-02 |
2015-05-28 |
Cancer Research Technology Limited |
Antibodies against hgf - receptor and uses
|
|
GB201122047D0
(en)
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
|
UY34486A
(es)
|
2011-12-05 |
2013-07-31 |
Novartis Ag |
Anticuerpos dirigidos al receptor del factor de crecimiento epidérmico 3 (her3) dirigidos contra el dominio ii del her3
|
|
KR102218497B1
(ko)
|
2011-12-05 |
2021-02-22 |
노파르티스 아게 |
표피 성장 인자 수용체 3 (her3)에 대한 항체
|
|
SG10201703249PA
(en)
|
2011-12-21 |
2017-05-30 |
Novartis Ag |
Compositions and methods for antibodies targeting factor p
|
|
US10112988B2
(en)
|
2012-01-09 |
2018-10-30 |
Icb International, Inc. |
Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
|
|
US10112987B2
(en)
|
2012-01-09 |
2018-10-30 |
Icb International, Inc. |
Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
|
|
WO2013108126A2
(en)
|
2012-01-16 |
2013-07-25 |
University Of Oslo |
Methyltransferases and uses thereof
|
|
CN104507967B
(zh)
|
2012-01-20 |
2018-10-12 |
建新公司 |
抗cxcr3抗体
|
|
EP2809800A1
(en)
|
2012-01-30 |
2014-12-10 |
VIB vzw |
Means and method for diagnosis and treatment of alzheimer's disease
|
|
WO2013121042A1
(en)
|
2012-02-16 |
2013-08-22 |
Vib Vzw |
PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
|
|
AU2013226340B2
(en)
|
2012-02-27 |
2017-06-22 |
Ablynx N.V. |
CX3CR1-binding polypeptides
|
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
|
JP6101782B2
(ja)
|
2012-03-27 |
2017-03-22 |
ヴェンタナ メディカル システムズ， インク． |
シグナリングコンジュゲート及び使用法
|
|
KR102020255B1
(ko)
|
2012-03-30 |
2019-09-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
Ang2 결합분자
|
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
EP2687595B1
(en)
|
2012-07-19 |
2018-05-30 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Method for purifying transgenic factor VII
|
|
KR102268351B1
(ko)
|
2012-07-25 |
2021-06-22 |
셀덱스 쎄라퓨틱스, 인크. |
항-kit 항체 및 그의 용도
|
|
US20150164800A1
(en)
|
2012-07-25 |
2015-06-18 |
Xetrios Therapeutics, Inc. |
Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine
|
|
US9605074B2
(en)
|
2012-08-30 |
2017-03-28 |
The General Hospital Corporation |
Multifunctional nanobodies for treating cancer
|
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
|
EP2906240A2
(en)
|
2012-10-09 |
2015-08-19 |
Biogen MA Inc. |
Combination therapies and uses for treatment of demyelinating disorders
|
|
MX359950B
(es)
|
2012-11-20 |
2018-10-17 |
Novartis Ag |
Casete de expresión optimizado para expresar un polipéptido con un alto rendimiento.
|
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
|
LT2928921T
(lt)
|
2012-12-05 |
2021-04-26 |
Novartis Ag |
Kompozicijos ir būdai, skirti antikūnams nukreipti į epo
|
|
WO2014087010A1
(en)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
|
|
HUE064063T2
(hu)
|
2012-12-14 |
2024-02-28 |
Omniab Inc |
Emberi idiotípusokat tartalmazó rágcsáló ellenanyagokat kódoló polinukleotidok és az ezeket tartalmazó állatok
|
|
JP2016502850A
(ja)
|
2012-12-18 |
2016-02-01 |
ノバルティス アーゲー |
ヒアルロナンに結合するペプチドタグを使用する組成物及び方法
|
|
JP2016505843A
(ja)
|
2012-12-19 |
2016-02-25 |
アンプリミューン， インコーポレイテッド |
Ｂ７−ｈ４特異的抗体、並びにその組成物及び使用方法
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
EP2935332B1
(en)
|
2012-12-21 |
2021-11-10 |
MedImmune, LLC |
Anti-h7cr antibodies
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
CN105102478A
(zh)
|
2013-01-30 |
2015-11-25 |
弗拉芒区生物技术研究所 |
用于筛选和药物发现目的的新型嵌合多肽
|
|
WO2014120916A1
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Pegylated domain antibodies monovalent for cd28 binding and methods of use
|
|
AU2014214054B2
(en)
|
2013-02-05 |
2018-10-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Muscarinic acetylcholine receptor binding agents and uses thereof
|
|
US9340618B2
(en)
|
2013-02-07 |
2016-05-17 |
Csl Limited |
IL-11R binding proteins
|
|
CA3185317A1
(en)
|
2013-02-08 |
2014-08-14 |
Novartis Ag |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
|
|
CN105143270B
(zh)
|
2013-02-26 |
2019-11-12 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
CA3175634A1
(en)
|
2013-02-28 |
2014-09-04 |
Caprion Proteomics Inc. |
Tuberculosis biomarkers and uses thereof
|
|
EP2972227B1
(en)
|
2013-03-12 |
2020-05-06 |
Ventana Medical Systems, Inc. |
Digitally enhanced microscopy for multiplexed histology
|
|
ES2766762T3
(es)
|
2013-03-13 |
2020-06-15 |
Prothena Biosciences Ltd |
Inmunoterapia contra Tau
|
|
EP3611189A1
(en)
|
2013-03-14 |
2020-02-19 |
Novartis AG |
Antibodies against notch 3
|
|
WO2014140376A1
(en)
|
2013-03-15 |
2014-09-18 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
|
|
EP2968508B1
(en)
|
2013-03-15 |
2022-04-27 |
Sanofi Pasteur Biologics, LLC |
Antibodies against clostridium difficile toxins and methods of using the same
|
|
EP4696718A2
(en)
|
2013-03-15 |
2026-02-18 |
Novartis AG |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
WO2014141192A1
(en)
|
2013-03-15 |
2014-09-18 |
Erasmus University Medical Center |
Generation of heavy chain-only antibodies
|
|
EP3831840A1
(en)
|
2013-03-15 |
2021-06-09 |
Celgene Corporation |
Modified t lymphocytes
|
|
US10233249B2
(en)
|
2013-03-19 |
2019-03-19 |
Beijing Shenogen Pharma Group Ltd. |
Antibodies and methods for treating estrogen receptor-associated diseases
|
|
HRP20192182T1
(hr)
|
2013-04-29 |
2020-02-21 |
Agrosavfe Nv |
Agrokemijski pripravci koji sadrže protutijela koja se vežu na sfingolipide
|
|
US10000556B2
(en)
|
2013-05-09 |
2018-06-19 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Single-domain VHH antibodies directed to norovirus GI.1 and GII.4 and their use
|
|
NL1040254C2
(en)
|
2013-05-17 |
2014-11-24 |
Ablynx Nv |
Stable formulations of immunoglobulin single variable domains and uses thereof.
|
|
KR20160129698A
(ko)
|
2013-05-24 |
2016-11-09 |
메디뮨 엘엘씨 |
항-b7-h5 항체 및 이의 용도
|
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
EP3003390B1
(en)
|
2013-06-06 |
2021-07-07 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
|
US9562101B2
(en)
|
2013-06-21 |
2017-02-07 |
Novartis Ag |
Lectin-like oxidized LDL receptor 1 antibodies and methods of use
|
|
EP3013356B1
(en)
|
2013-06-27 |
2018-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases
|
|
US20160176943A1
(en)
|
2013-07-05 |
2016-06-23 |
Inserm (Insititut National De La Sante Et De La Recherche Medicale) |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
|
WO2015004632A1
(en)
|
2013-07-12 |
2015-01-15 |
Neotope Biosciences Limited |
Antibodies that recognize iapp
|
|
WO2015004633A1
(en)
|
2013-07-12 |
2015-01-15 |
Neotope Biosciences Limited |
Antibodies that recognize islet-amyloid polypeptide (iapp)
|
|
SI3011345T1
(sl)
|
2013-08-07 |
2017-12-29 |
Alexion Pharmaceuticals, Inc. |
Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
|
|
MX2016001969A
(es)
|
2013-08-14 |
2016-06-02 |
Novartis Ag |
Metodos para tratar la miositis por cuerpos de inclusion esporadica.
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
KR102339724B1
(ko)
|
2013-11-28 |
2021-12-17 |
씨에스엘 리미티드 |
신장병증의 치료 방법
|
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
|
CN105979965B
(zh)
|
2013-12-18 |
2021-07-09 |
杰特有限公司 |
治疗伤口的方法
|
|
CA3225453A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
PT3083694T
(pt)
|
2013-12-20 |
2024-02-01 |
Intervet Int Bv |
Anticorpos murinos caninizados anti-pd-1 canino
|
|
WO2015100409A2
(en)
|
2013-12-26 |
2015-07-02 |
Tufts University |
Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
EP3099707B1
(en)
|
2014-01-30 |
2021-12-29 |
Vib Vzw |
Opioid receptor binding agents and uses thereof
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
CA3212977A1
(en)
|
2014-02-11 |
2015-08-20 |
Visterra, Inc. |
Antibody molecules to dengue virus and uses thereof
|
|
WO2015123687A1
(en)
|
2014-02-14 |
2015-08-20 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
PH12016501545B1
(en)
|
2014-03-14 |
2023-12-06 |
Immutep Sas |
Antibody molecules to lag-3 and uses thereof
|
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
|
EP3811970A1
(en)
|
2014-03-15 |
2021-04-28 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
EP3895528A1
(en)
|
2014-03-21 |
2021-10-20 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
SG11201607015VA
(en)
|
2014-03-21 |
2016-09-29 |
Regeneron Pharma |
V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
|
|
WO2015155694A1
(en)
|
2014-04-08 |
2015-10-15 |
Prothena Biosciences Limited |
Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
|
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
|
DK3689899T3
(da)
|
2014-04-25 |
2021-11-22 |
2Seventy Bio Inc |
Kimære mnd-promotor-antigenreceptorer
|
|
CN106456670B
(zh)
|
2014-04-25 |
2020-01-07 |
蓝鸟生物公司 |
制备过继性细胞疗法的改善方法
|
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
|
IL318433A
(en)
|
2014-05-16 |
2025-03-01 |
Ablynx Nv |
Improved immunoglobulin variable complexes
|
|
WO2015173325A2
(en)
|
2014-05-16 |
2015-11-19 |
Ablynx Nv |
Improved immunoglobulin variable domains
|
|
EA201692458A1
(ru)
|
2014-05-28 |
2017-06-30 |
Агенус Инк. |
Анти-gitr антитела и способы их применения
|
|
AU2015269197B2
(en)
|
2014-06-06 |
2018-10-04 |
2Seventy Bio, Inc. |
Improved T cell compositions
|
|
NL2013007B1
(en)
|
2014-06-16 |
2016-07-05 |
Ablynx Nv |
Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
|
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
|
EP3161001A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
|
WO2015198243A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
|
US20170327553A1
(en)
|
2014-06-25 |
2017-11-16 |
Novartis Ag |
Compositions and methods for long acting proteins
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
RU2751660C2
(ru)
|
2014-07-21 |
2021-07-15 |
Новартис Аг |
Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
PT3194976T
(pt)
|
2014-07-22 |
2020-07-03 |
Univ Brussel Vrije |
Métodos para selecionar agentes que estabilizam complexos proteicos
|
|
CA2956002C
(en)
|
2014-07-24 |
2023-06-27 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
US20180036442A1
(en)
|
2014-07-29 |
2018-02-08 |
Vrije Universiteit Brussel |
Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
|
|
CA2954359C
(en)
|
2014-07-29 |
2018-09-25 |
Vrije Universiteit Brussel |
Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
|
|
WO2016019300A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
US9988443B2
(en)
|
2014-08-07 |
2018-06-05 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
|
CN107148428B
(zh)
|
2014-08-07 |
2021-03-09 |
诺华股份有限公司 |
血管生成素样蛋白4抗体和使用方法
|
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
|
|
CN112410363A
(zh)
|
2014-08-19 |
2021-02-26 |
诺华股份有限公司 |
抗cd123嵌合抗原受体(car)用于癌症治疗
|
|
KR102321168B1
(ko)
|
2014-08-19 |
2021-11-02 |
머크 샤프 앤드 돔 코포레이션 |
항-tigit 항체
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
WO2016040880A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
|
WO2016044605A1
(en)
|
2014-09-17 |
2016-03-24 |
Beatty, Gregory |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
MY203626A
(en)
|
2014-10-03 |
2024-07-10 |
Nanotics Llc |
Compositions and methods for inhibiting the biological activity of soluble biomolecules
|
|
EP3662903A3
(en)
|
2014-10-03 |
2020-10-14 |
Novartis AG |
Combination therapies
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
RU2017115670A
(ru)
|
2014-10-10 |
2018-11-15 |
Аблинкс Н.В. |
Лечение инфекции рсв
|
|
AU2015329935B2
(en)
|
2014-10-10 |
2019-09-19 |
Ablynx N.V. |
Inhalation device for use in aerosol therapy of respiratory diseases
|
|
KR102513870B1
(ko)
|
2014-10-14 |
2023-03-23 |
노파르티스 아게 |
Pd-l1에 대한 항체 분자 및 그의 용도
|
|
AU2015336946A1
(en)
|
2014-10-23 |
2017-04-13 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
|
CA2966548A1
(en)
|
2014-11-05 |
2016-05-12 |
Agrosavfe Nv |
Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody
|
|
WO2021173560A1
(en)
|
2020-02-24 |
2021-09-02 |
Immatics US, Inc. |
Methods for expanding t cells for the treatment of cancer and related malignancies
|
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
|
WO2016094602A1
(en)
|
2014-12-10 |
2016-06-16 |
Tufts University |
Vhh based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
|
|
LT3333191T
(lt)
|
2014-12-11 |
2020-12-10 |
Pierre Fabre Médicament |
Anti-c10orf54 antikūnai ir jų panaudojimas
|
|
WO2016094834A2
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
A method for treating a complement mediated disorder caused by an infectious agent in a patient
|
|
HRP20211648T1
(hr)
|
2014-12-12 |
2022-02-04 |
2Seventy Bio, Inc. |
Kimerni receptori antigena bcma
|
|
PL3233910T3
(pl)
|
2014-12-19 |
2020-06-01 |
Ablynx N.V. |
Dimery nanociał połączone cysteiną
|
|
AU2015367224B2
(en)
|
2014-12-19 |
2020-12-10 |
Monash University |
IL-21 antibodies
|
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
|
EP3237450B1
(en)
|
2014-12-22 |
2021-03-03 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
|
TW201631152A
(zh)
|
2014-12-29 |
2016-09-01 |
諾華公司 |
製造嵌合抗原受體－表現細胞之方法
|
|
SG10202007176TA
(en)
|
2014-12-30 |
2020-08-28 |
Celgene Corp |
Anti-cd47 antibodies and uses thereof
|
|
ES2856844T3
(es)
|
2014-12-31 |
2021-09-28 |
Checkmate Pharmaceuticals Inc |
Inmunoterapia antitumoral combinada
|
|
HK1246810A1
(zh)
|
2015-01-08 |
2018-09-14 |
Biogen Ma Inc. |
Lingo-1对抗药及用於治疗脱髓鞘疾病的用途
|
|
GB201501004D0
(en)
|
2015-01-21 |
2015-03-04 |
Cancer Rec Tech Ltd |
Inhibitors
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
EP3254110B1
(en)
|
2015-02-03 |
2020-03-18 |
Ventana Medical Systems, Inc. |
Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
|
|
US10544210B2
(en)
|
2015-02-03 |
2020-01-28 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-Rho GTPase conformational single domain antibodies and uses thereof
|
|
WO2016128549A1
(en)
|
2015-02-13 |
2016-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
|
|
US10301377B2
(en)
|
2015-02-24 |
2019-05-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
EP3061826A1
(en)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus replicons
|
|
CA2968642A1
(en)
|
2015-03-03 |
2016-09-09 |
Kymab Limited |
Antibodies, uses & methods
|
|
AU2016233309B2
(en)
|
2015-03-17 |
2021-11-18 |
Memorial Sloan Kettering Cancer Center |
Anti-MUC16 antibodies and uses thereof
|
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
AU2016232715A1
(en)
|
2015-03-19 |
2017-09-28 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
EP3274724A1
(en)
|
2015-03-25 |
2018-01-31 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of factor d of the alternative complement pathway
|
|
EP3274468B1
(en)
|
2015-03-25 |
2019-02-20 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway
|
|
HK1250040A1
(zh)
|
2015-03-31 |
2018-11-23 |
Sorriso Pharmaceuticals, Inc. |
多肽
|
|
ES2913200T3
(es)
|
2015-03-31 |
2022-06-01 |
Sorriso Pharmaceuticals Inc |
Polipéptidos
|
|
WO2016156466A1
(en)
|
2015-03-31 |
2016-10-06 |
Vhsquared Limited |
Peptide construct having a protease-cleavable linker
|
|
WO2016156588A1
(en)
|
2015-04-02 |
2016-10-06 |
Intervet International B.V. |
Antibodies to canine interleukin-4 receptor alpha
|
|
EP3277316B1
(en)
|
2015-04-02 |
2025-03-05 |
Ablynx N.V. |
Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
|
|
EP3280795B1
(en)
|
2015-04-07 |
2021-03-24 |
Novartis AG |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
WO2016166110A1
(en)
|
2015-04-13 |
2016-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
|
|
US9778265B2
(en)
|
2015-04-16 |
2017-10-03 |
The United States Of America, As Represented By The Secretary Of The Navy |
Charged peptide appendage to facilitate oriented protein covalent immobilization
|
|
EP3283529B1
(en)
|
2015-04-17 |
2023-06-07 |
The General Hospital Corporation |
Agents, systems and methods for treating cancer
|
|
CN118726268A
(zh)
|
2015-04-17 |
2024-10-01 |
诺华股份有限公司 |
改善嵌合抗原受体表达细胞的功效和扩增的方法
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
MX2017014188A
(es)
|
2015-05-07 |
2018-04-10 |
Agenus Inc |
Anticuerpos anti-ox40 y metodos para su uso.
|
|
EP3736287A1
(en)
|
2015-05-11 |
2020-11-11 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
|
PT3611192T
(pt)
|
2015-05-13 |
2025-06-12 |
Ablynx Nv |
Polipéptidos de recrutamento de células t com base na reatividade do tcr alfa/beta
|
|
AU2016260909B2
(en)
|
2015-05-13 |
2019-08-22 |
Ablynx N.V. |
T cell recruiting polypeptides based on CD3 reactivity
|
|
US9708412B2
(en)
|
2015-05-21 |
2017-07-18 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
US10294306B2
(en)
|
2015-05-28 |
2019-05-21 |
Bio-Rad Laboratories, Inc. |
Affinity ligands and methods relating thereto
|
|
CN107849144B
(zh)
|
2015-05-29 |
2021-09-17 |
艾吉纳斯公司 |
抗-ctla-4抗体及其使用方法
|
|
CA2982237A1
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
|
US10696745B2
(en)
|
2015-06-11 |
2020-06-30 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Anti-PD-L1 antibodies
|
|
US10782304B2
(en)
|
2015-06-24 |
2020-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for detecting protein-protein interactions
|
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
|
CN108025093B
(zh)
|
2015-07-17 |
2022-02-11 |
布鲁塞尔自由大学 |
用于在治疗癌症中使用的放射性标记的抗体片段
|
|
CA2992551A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
EP3964528A1
(en)
|
2015-07-29 |
2022-03-09 |
Novartis AG |
Combination therapies comprising antibody molecules to lag-3
|
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
US20190008983A1
(en)
|
2015-07-31 |
2019-01-10 |
James R. Prudent |
Extracellular drug conjugates targeting cd20
|
|
CN108472314A
(zh)
|
2015-07-31 |
2018-08-31 |
明尼苏达大学董事会 |
修饰的细胞和治疗方法
|
|
CN108350072B
(zh)
|
2015-08-03 |
2022-05-24 |
诺华股份有限公司 |
治疗fgf21相关病症的方法
|
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
ES2855998T3
(es)
|
2015-08-07 |
2021-09-27 |
Merck Patent Gmbh |
Etiqueta transglutamina para bioconjugación específica de sitio eficiente
|
|
LT3334763T
(lt)
|
2015-08-11 |
2025-01-10 |
WuXi Biologics Ireland Limited |
Nauji anti-pd-1 antikūnai
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
EP4014996A1
(en)
|
2015-08-31 |
2022-06-22 |
Helixmith Co., Ltd |
Anti-sialyl tn chimeric antigen receptors
|
|
MA48579A
(fr)
|
2015-09-01 |
2020-03-18 |
Agenus Inc |
Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
|
|
CN116334205A
(zh)
|
2015-09-03 |
2023-06-27 |
诺华股份有限公司 |
预测细胞因子释放综合征的生物标志物
|
|
NZ740067A
(en)
|
2015-09-09 |
2021-07-30 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
|
US10000561B2
(en)
|
2015-09-09 |
2018-06-19 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
|
|
HK1251480A1
(zh)
|
2015-09-21 |
2019-02-01 |
Aptevo Research And Development Llc |
Cd3结合多肽
|
|
EP3359566A1
(en)
|
2015-10-07 |
2018-08-15 |
Alexion Pharmaceuticals, Inc. |
A method for treating age-related macular degeneration in a patient
|
|
EP3359668A4
(en)
|
2015-10-09 |
2019-06-05 |
Sarepta Therapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATING DUCHENNE MUSCLE DYSTROPHY AND ASSOCIATED ILLNESSES THEREOF
|
|
CN105238759B
(zh)
*
|
2015-10-14 |
2019-05-24 |
吉日木图 |
抗驼乳重链IgG3单克隆抗体、含有所述单克隆抗体的试纸及其应用
|
|
GB201518675D0
(en)
|
2015-10-21 |
2015-12-02 |
Cellcap Technologies Ltd |
Detection of structural forms of proteins
|
|
JP7041628B2
(ja)
|
2015-11-10 |
2022-03-24 |
ビステラ， インコーポレイテッド |
リポ多糖に特異的に結合する抗体分子－薬物コンジュゲートおよびその使用
|
|
NO2768984T3
(fi)
|
2015-11-12 |
2018-06-09 |
|
|
|
US20180327499A1
(en)
|
2015-11-13 |
2018-11-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- nkg2d single domain antibodies and uses thereof
|
|
KR102095140B1
(ko)
|
2015-11-18 |
2020-03-31 |
머크 샤프 앤드 돔 코포레이션 |
Ctla4 결합제
|
|
MA43260A
(fr)
|
2015-11-18 |
2018-09-26 |
Merck Sharp & Dohme |
Liants pd1 et/ou lag3
|
|
SG11201804309PA
(en)
|
2015-11-25 |
2018-06-28 |
Visterra Inc |
Antibody molecules to april and uses thereof
|
|
US10894834B2
(en)
|
2015-11-27 |
2021-01-19 |
Csl Limited |
CD131 binding proteins
|
|
CN108473561B
(zh)
|
2015-11-27 |
2022-12-16 |
埃博灵克斯股份有限公司 |
抑制cd40l的多肽
|
|
PH12018501155B1
(en)
|
2015-12-04 |
2024-06-28 |
Boehringer Ingelheim Int |
Biparatopic polypeptides antagonizing wnt signaling in tumor cells
|
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
|
WO2017097889A1
(en)
|
2015-12-10 |
2017-06-15 |
Katholieke Universiteit Leuven |
Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
|
|
EP3399989B1
(en)
|
2015-12-16 |
2023-08-09 |
Merck Sharp & Dohme LLC |
Anti-lag3 antibodies and antigen-binding fragments
|
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子およびその使用
|
|
US20200261573A1
(en)
|
2015-12-17 |
2020-08-20 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
|
US11091556B2
(en)
|
2015-12-18 |
2021-08-17 |
Intervet Inc. |
Caninized human antibodies to human IL-4R alpha
|
|
CN109069623A
(zh)
|
2015-12-18 |
2018-12-21 |
诺华股份有限公司 |
靶向CD32b的抗体及其使用方法
|
|
ES3014160T3
(en)
|
2015-12-18 |
2025-04-21 |
Intervet Int Bv |
Caninized human antibodies to human and canine il-4r alpha
|
|
CN109069597A
(zh)
|
2015-12-22 |
2018-12-21 |
诺华股份有限公司 |
间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
|
|
JP2019500874A
(ja)
|
2015-12-28 |
2019-01-17 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞の作製方法
|
|
US11001631B2
(en)
|
2016-02-05 |
2021-05-11 |
Orionis Biosciences BV |
Clec9A binding agents
|
|
MX2018010021A
(es)
|
2016-02-17 |
2018-11-09 |
Novartis Ag |
Anticuerpos anti tgfbeta 2.
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
EP3426278B1
(en)
|
2016-03-07 |
2024-01-03 |
Vib Vzw |
Cd20 binding single domain antibodies
|
|
CA3017776A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
|
WO2017158396A1
(en)
|
2016-03-16 |
2017-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cytidine deaminase inhibitors for the treatment of pancreatic cancer
|
|
EP3433615A1
(en)
|
2016-03-21 |
2019-01-30 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods for diagnosis and treatment of solar lentigo
|
|
AU2017238172B2
(en)
|
2016-03-21 |
2024-06-27 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
JP7080213B2
(ja)
|
2016-03-23 |
2022-06-03 |
スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド |
新規抗ｐｄ－ｌ１抗体
|
|
MA44483A
(fr)
|
2016-03-24 |
2019-01-30 |
Millennium Pharm Inc |
Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
|
|
WO2017165742A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
|
|
AU2017238651B2
(en)
|
2016-03-25 |
2024-06-13 |
Visterra, Inc. |
Formulation of antibody molecules to dengue virus
|
|
WO2017176762A1
(en)
|
2016-04-06 |
2017-10-12 |
Nanotics, Llc |
Particles comprising subparticles or nucleic acid scaffolds
|
|
EP3442993B1
(en)
|
2016-04-13 |
2021-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for the rapid detection of the escherichia coli o25b-st131 clone
|
|
WO2017180993A1
(en)
|
2016-04-14 |
2017-10-19 |
Bluebird Bio, Inc. |
Salvage chimeric antigen receptor systems
|
|
IL262321B2
(en)
|
2016-04-15 |
2024-09-01 |
Novartis Ag |
Preparations and methods for selective protein expression
|
|
WO2017181098A2
(en)
|
2016-04-15 |
2017-10-19 |
Visterra, Inc. |
Antibody molecules to zika virus and uses thereof
|
|
EP3445393B1
(en)
|
2016-04-20 |
2026-01-14 |
Merck Sharp & Dohme LLC |
Cmv neutralizing antigen binding proteins
|
|
WO2017182605A1
(en)
|
2016-04-22 |
2017-10-26 |
Université Libre de Bruxelles |
A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
|
|
US11243214B2
(en)
|
2016-04-22 |
2022-02-08 |
Université Libre de Bruxelles |
Biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
|
|
WO2017189724A1
(en)
|
2016-04-27 |
2017-11-02 |
Novartis Ag |
Antibodies against growth differentiation factor 15 and uses thereof
|
|
US20190127447A1
(en)
|
2016-05-02 |
2019-05-02 |
Ablynx N.V. |
Treatment of rsv infection
|
|
ES2933491T3
(es)
|
2016-05-02 |
2023-02-09 |
Prothena Biosciences Ltd |
Inmunoterapia tau
|
|
CN109563141A
(zh)
|
2016-05-13 |
2019-04-02 |
奥里尼斯生物科学公司 |
对非细胞结构的治疗性靶向
|
|
IL262892B2
(en)
|
2016-05-18 |
2024-04-01 |
Boehringer Ingelheim Int |
Anti pd-1 and anti-lag3 antibodies for cancer treatment
|
|
WO2017201488A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
|
ES3036522T3
(en)
|
2016-05-20 |
2025-09-19 |
Harpoon Therapeutics Inc |
Single chain variable fragment cd3 binding proteins
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
EP3463452A1
(en)
|
2016-05-24 |
2019-04-10 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
|
SG10201912563XA
(en)
|
2016-05-27 |
2020-02-27 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
|
KR20190012199A
(ko)
|
2016-05-27 |
2019-02-08 |
알렉시온 파마슈티칼스, 인코포레이티드 |
난치성 전신 중증 근무력증의 치료를 위한 방법
|
|
WO2017213695A1
(en)
|
2016-06-07 |
2017-12-14 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions
|
|
JP7231411B2
(ja)
|
2016-06-15 |
2023-03-01 |
ノバルティス アーゲー |
骨形成タンパク質６（ｂｍｐ６）の阻害剤を使用して疾患を処置する方法
|
|
US11197902B2
(en)
|
2016-06-24 |
2021-12-14 |
Ig Biosciences Corporation |
Prebiotic neutraceutical compositions and methods of treatment using the same
|
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
|
KR20190039937A
(ko)
|
2016-07-08 |
2019-04-16 |
스태튼 바이오테크놀로지 비.브이. |
항-ApoC3 항체 및 이의 사용 방법
|
|
JP7149257B2
(ja)
|
2016-07-13 |
2022-10-06 |
バイオジェン・エムエイ・インコーポレイテッド |
Ｌｉｎｇｏ－１アンタゴニストの投与計画及び脱髄障害の処置のための使用
|
|
SG11201900344YA
(en)
|
2016-07-15 |
2019-02-27 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
WO2018017964A2
(en)
|
2016-07-21 |
2018-01-25 |
Emory University |
Ebola virus antibodies and binding agents derived therefrom
|
|
KR20230100748A
(ko)
|
2016-07-28 |
2023-07-05 |
노파르티스 아게 |
키메라 항원 수용체 및 pd-1 억제제의 조합 요법
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
BR112019002035A2
(pt)
|
2016-08-01 |
2019-05-14 |
Novartis Ag |
tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2
|
|
DK3494134T3
(da)
|
2016-08-02 |
2026-02-09 |
Visterra Inc |
Manipulerede polypeptider og deres anvendelse
|
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
CA3032826A1
(en)
|
2016-08-03 |
2018-02-08 |
Nextcure, Inc. |
Compositions and methods for modulating lair signal transduction
|
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
|
US11098113B2
(en)
|
2016-09-15 |
2021-08-24 |
Vib Vzw |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
|
JP2020502991A
(ja)
|
2016-09-20 |
2020-01-30 |
ウーシー バイオロジクス アイルランド リミテッド |
新規抗ｐｃｓｋ９抗体
|
|
CN110035769A
(zh)
|
2016-09-21 |
2019-07-19 |
奈斯科尔公司 |
针对siglec-15的抗体及其使用方法
|
|
EP4360714A3
(en)
|
2016-09-21 |
2024-07-24 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
|
WO2018057955A1
(en)
|
2016-09-23 |
2018-03-29 |
Elstar Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
|
CN110023339A
(zh)
|
2016-09-23 |
2019-07-16 |
Csl有限公司 |
凝血因子结合蛋白及其应用
|
|
WO2018060453A1
(en)
|
2016-09-30 |
2018-04-05 |
Vhsquared Limited |
Compositions
|
|
TWI797091B
(zh)
|
2016-10-07 |
2023-04-01 |
瑞士商諾華公司 |
利用嵌合抗原受體之癌症治療
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
KR102576042B1
(ko)
|
2016-10-11 |
2023-09-07 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
JP7256741B2
(ja)
|
2016-10-12 |
2023-04-12 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性
|
|
CA3041068A1
(en)
|
2016-10-18 |
2018-04-26 |
Regents Of The University Of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
WO2018075761A1
(en)
|
2016-10-19 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
A method of quantitating unbound c5a in a sample
|
|
US11965884B2
(en)
|
2016-10-19 |
2024-04-23 |
Alexion Pharmaceuticals, Inc. |
Method of quantitating unbound C5 in a sample
|
|
PL3529262T3
(pl)
|
2016-10-21 |
2021-12-27 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Sposoby wspomagania odpowiedzi limfocytów t
|
|
EP3532845A1
(en)
|
2016-10-27 |
2019-09-04 |
Alexion Pharmaceuticals, Inc. |
Assay for c5b-9 deposition in complement-associated disorders
|
|
WO2018078083A1
(en)
|
2016-10-28 |
2018-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating multiple myeloma
|
|
US20190263926A1
(en)
|
2016-10-28 |
2019-08-29 |
Astute Medical, Inc. |
Use of Antibodies to TIMP-2 for the Improvement of Renal Function
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
EP3534968A4
(en)
|
2016-11-04 |
2020-07-01 |
Bluebird Bio, Inc. |
ANTI-BCMA T CAR LYMPHOCYTE COMPOSITIONS
|
|
KR102431830B1
(ko)
|
2016-11-07 |
2022-08-16 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
|
IL266506B2
(en)
|
2016-11-16 |
2025-05-01 |
Ablynx Nv |
T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
|
|
EP4353822A3
(en)
|
2016-11-17 |
2024-07-03 |
2seventy bio, Inc. |
Tgf beta signal convertor
|
|
US11773163B2
(en)
|
2016-11-21 |
2023-10-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the prophylactic treatment of metastases
|
|
WO2018098356A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Psma targeting trispecific proteins and methods of use
|
|
EP3544997A4
(en)
|
2016-11-23 |
2020-07-01 |
Harpoon Therapeutics, Inc. |
PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
|
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
|
WO2018102746A1
(en)
|
2016-12-02 |
2018-06-07 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to tigit
|
|
CN118634323A
(zh)
|
2016-12-07 |
2024-09-13 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
SI3551660T1
(sl)
|
2016-12-07 |
2024-02-29 |
Agenus Inc. |
Protitelesa proti antictla-4 in načini njihove uporabe
|
|
EP3551034A1
(en)
|
2016-12-07 |
2019-10-16 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
US11426566B2
(en)
|
2016-12-14 |
2022-08-30 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a TLR modulator
|
|
CN110167589B
(zh)
|
2016-12-14 |
2023-05-16 |
比奥拉治疗股份有限公司 |
使用整联蛋白抑制剂治疗胃肠道疾病
|
|
MX2019006823A
(es)
|
2016-12-14 |
2019-10-21 |
Progenity Inc |
Tratamiento de una enfermedad del tracto gastrointestinal con inhibidor de interleucina-12/interleucina-23 (il-12/il-23) liberado usando un dispositivo ingerible.
|
|
WO2018112235A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
|
WO2018112264A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
|
US20200315540A1
(en)
|
2016-12-14 |
2020-10-08 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
|
JP2020513280A
(ja)
|
2016-12-14 |
2020-05-14 |
プロジェニティ， インコーポレイテッド |
消化管疾病の免疫抑制剤による治療
|
|
JP7150724B2
(ja)
|
2016-12-14 |
2022-10-11 |
ビオラ・セラピューティクス・インコーポレイテッド |
消化管疾病のｔｎｆ阻害薬による治療
|
|
WO2018112245A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
|
|
EP3360898A1
(en)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
|
|
IL267565B2
(en)
|
2016-12-23 |
2025-02-01 |
Visterra Inc |
Methods of producing binding polypeptides containing covalently linked heavy chains and light chains
|
|
CN110325550B
(zh)
|
2016-12-23 |
2024-03-08 |
诺华股份有限公司 |
因子xi抗体和使用方法
|
|
EP3565560B1
(en)
|
2017-01-09 |
2024-05-29 |
OnkosXcel Therapeutics, LLC |
Predictive and diagnostic methods for prostate cancer
|
|
WO2018136626A1
(en)
|
2017-01-18 |
2018-07-26 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
|
SG11201906540WA
(en)
|
2017-01-19 |
2019-08-27 |
Open Monoclonal Tech Inc |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
WO2018141753A1
(en)
|
2017-01-31 |
2018-08-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating squamous cell carcinomas
|
|
US11384154B2
(en)
|
2017-02-06 |
2022-07-12 |
Orionis Biosciences BV |
Targeted chimeric proteins and uses thereof
|
|
DK3580237T3
(da)
|
2017-02-08 |
2025-06-30 |
Novartis Ag |
Fgf21-mimetiske antistoffer og anvendelser deraf
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
EP3589662A4
(en)
|
2017-02-28 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
|
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
US11964002B2
(en)
|
2017-02-28 |
2024-04-23 |
Vib Vzw |
Means and methods for oral protein delivery
|
|
WO2018161017A1
(en)
|
2017-03-03 |
2018-09-07 |
Obsidian Therapeutics, Inc. |
Cd19 compositions and methods for immunotherapy
|
|
WO2018160993A1
(en)
|
2017-03-03 |
2018-09-07 |
Obsidian Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
EP3943940A1
(en)
|
2017-03-14 |
2022-01-26 |
NanoTag Biotechnologies GmbH |
Target detection using a monovalent antibody
|
|
US10941203B2
(en)
|
2017-03-15 |
2021-03-09 |
Tsinghua University |
Anti-TrkB agonist antibodies binding to D5 domain of TrkB and methods of promoting neuronal survival in motor neuron injury, stroke or glaucoma
|
|
WO2018167283A1
(en)
|
2017-03-17 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
|
|
HRP20251505T1
(hr)
|
2017-03-24 |
2026-01-02 |
Novartis Ag |
Protutijelo protiv aktivinskog receptora tipa ii za upotrebu u liječenju zatajenja srca
|
|
KR20190133198A
(ko)
|
2017-03-27 |
2019-12-02 |
셀진 코포레이션 |
면역원성의 감소를 위한 방법 및 조성물
|
|
EP3600414A1
(en)
|
2017-03-30 |
2020-02-05 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
|
|
WO2018183934A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
|
CA3054947A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with live biotherapeutics
|
|
CA3054632A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
AU2018249493A1
(en)
|
2017-04-03 |
2019-09-19 |
Oncxerna Therapeutics, Inc. |
Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
|
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
|
US20200088732A1
(en)
|
2017-04-13 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Mèdicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
|
|
TWI842672B
(zh)
|
2017-04-13 |
2024-05-21 |
美商艾吉納斯公司 |
抗ｃｄ１３７抗體及其使用方法
|
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
|
WO2018192974A1
(en)
|
2017-04-18 |
2018-10-25 |
Université Libre de Bruxelles |
Biomarkers and targets for proliferative diseases
|
|
US20200123238A1
(en)
|
2017-04-19 |
2020-04-23 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
|
|
EP3612563A1
(en)
|
2017-04-19 |
2020-02-26 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
KR20190141659A
(ko)
|
2017-04-21 |
2019-12-24 |
스태튼 바이오테크놀로지 비.브이. |
항-apoc3 항체 및 이의 사용 방법
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
CA3059769A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
|
WO2018204363A1
(en)
|
2017-05-01 |
2018-11-08 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
|
EP3621990A1
(en)
|
2017-05-11 |
2020-03-18 |
VIB vzw |
Glycosylation of variable immunoglobulin domains
|
|
US11041011B2
(en)
|
2017-05-12 |
2021-06-22 |
Augusta University Research Institute, Inc. |
Human alpha fetoprotein-specific murine T cell receptors and uses thereof
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
US10730954B2
(en)
|
2017-05-12 |
2020-08-04 |
Harpoon Therapeutics, Inc. |
MSLN targeting trispecific proteins and methods of use
|
|
CN113896792B
(zh)
|
2017-05-12 |
2025-08-22 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
|
WO2018222587A1
(en)
|
2017-05-30 |
2018-12-06 |
The Regents Of The University Of California |
NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
|
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
EP3630816B1
(en)
|
2017-05-31 |
2024-03-20 |
Boehringer Ingelheim International GmbH |
Polypeptides antagonizing wnt signaling in tumor cells
|
|
KR102778120B1
(ko)
|
2017-06-02 |
2025-03-06 |
메르크 파텐트 게엠베하 |
Mmp13 결합성 면역글로불린
|
|
TW202428621A
(zh)
|
2017-06-02 |
2024-07-16 |
德商麥克專利有限公司 |
與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
|
|
LT3630847T
(lt)
|
2017-06-02 |
2024-12-10 |
Merck Patent Gmbh |
Adamts surišantys imunoglobulinai
|
|
CN110691790A
(zh)
|
2017-06-02 |
2020-01-14 |
勃林格殷格翰国际有限公司 |
抗癌联合治疗
|
|
KR102800125B1
(ko)
|
2017-06-02 |
2025-04-24 |
아블린쓰 |
아그레칸 결합 면역글로불린
|
|
EP3415010A1
(en)
|
2017-06-13 |
2018-12-19 |
Agrosavfe Nv |
Insect-controlling polypeptides and methods
|
|
GB201709379D0
(en)
|
2017-06-13 |
2017-07-26 |
Univ Leuven Kath |
Humanised ADAMTS13 binding antibodies
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
|
MA49457A
(fr)
|
2017-06-22 |
2020-04-29 |
Novartis Ag |
Molécules d'anticorps se liant à cd73 et leurs utilisations
|
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
KR102574549B1
(ko)
|
2017-06-27 |
2023-09-07 |
주식회사 뉴라클사이언스 |
항-fam19a5 항체 및 이의 용도
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2019006007A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
|
|
JP2020525421A
(ja)
|
2017-06-28 |
2020-08-27 |
ノバルティス アーゲー |
尿失禁を予防及び治療するための方法
|
|
CA3068672A1
(en)
|
2017-06-28 |
2019-01-03 |
The Rockefeller University |
Anti-mertk agonistic antibody-drug conjugates and uses thereof
|
|
CN111511375A
(zh)
|
2017-06-30 |
2020-08-07 |
因提玛生物科学公司 |
用于基因治疗的腺相关病毒载体
|
|
CN118812712A
(zh)
|
2017-07-11 |
2024-10-22 |
指南针制药有限责任公司 |
结合人cd137的激动剂抗体及其用途
|
|
BR112019028269A2
(pt)
|
2017-07-11 |
2020-07-14 |
Alexion Pharmaceuticals, Inc. |
polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
|
|
WO2019012030A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
|
|
EP3431496A1
(en)
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti- isoasp7 amyloid beta antibodies and uses thereof
|
|
US11155607B2
(en)
|
2017-07-19 |
2021-10-26 |
Vib Vzw |
Serum albumin binding agents
|
|
AU2018302283B2
(en)
|
2017-07-20 |
2025-07-10 |
Novartis Ag |
Dosage regimens of anti-LAG-3 antibodies and uses thereof
|
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
|
WO2019020480A1
(en)
|
2017-07-24 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
|
|
SI3658184T1
(sl)
|
2017-07-27 |
2024-01-31 |
Alexion Pharmaceuticals, Inc., |
Formulacije z visoko koncentracijo protiteles proti-C5
|
|
WO2019028172A1
(en)
|
2017-08-01 |
2019-02-07 |
Compass Therapeutics Llc |
FILTRATION AND CHROMATOGRAPHY CAPSULES AND METHODS OF USE
|
|
WO2019036363A1
(en)
|
2017-08-14 |
2019-02-21 |
Progenity Inc. |
TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
EP3684811A2
(en)
|
2017-08-17 |
2020-07-29 |
Massachusetts Institute of Technology |
Multiple specificity binders of cxc chemokines and uses thereof
|
|
JP7795860B2
(ja)
|
2017-09-07 |
2026-01-08 |
オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド |
プログラム細胞死タンパク質１に対する抗体
|
|
CN111670198B
(zh)
|
2017-09-11 |
2023-12-15 |
莫纳什大学 |
人凝血酶受体par4的结合蛋白
|
|
US20200268837A1
(en)
|
2017-09-20 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating autophagy
|
|
CN119192374A
(zh)
|
2017-10-02 |
2024-12-27 |
威特拉公司 |
Cd138抗体分子及其用途
|
|
ES2759622T3
(es)
|
2017-10-02 |
2020-05-11 |
Certest Biotec S L |
Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
|
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
BR112020007196A2
(pt)
|
2017-10-13 |
2020-12-01 |
Harpoon Therapeutics, Inc. |
proteínas triespecíficas e métodos de uso
|
|
JP7395471B2
(ja)
|
2017-10-13 |
2023-12-11 |
オーセ イミュノセラピューティクス |
改変抗ＳＩＲＰａ抗体及びその使用
|
|
KR102715492B1
(ko)
|
2017-10-18 |
2024-10-11 |
씨에스엘 리미티드 |
인간 혈청 알부민 변이체 및 이의 용도
|
|
CN111655725A
(zh)
|
2017-10-19 |
2020-09-11 |
德比奥药物国际股份有限公司 |
用于治疗癌症的组合产品
|
|
SG11202003177RA
(en)
|
2017-10-25 |
2020-05-28 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
KR20240162603A
(ko)
|
2017-10-26 |
2024-11-15 |
알렉시온 파마슈티칼스, 인코포레이티드 |
발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
WO2019089798A1
(en)
|
2017-10-31 |
2019-05-09 |
Novartis Ag |
Anti-car compositions and methods
|
|
JP7760115B2
(ja)
|
2017-10-31 |
2025-10-27 |
フエー・イー・ベー・フエー・ゼツト・ウエー |
新規抗原結合性キメラタンパク質とその方法及び使用
|
|
EP3704148A1
(en)
|
2017-10-31 |
2020-09-09 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
WO2019090148A2
(en)
|
2017-11-03 |
2019-05-09 |
Rubius Therapeutics, Inc. |
Compositions and methods related to therapeutic cell systems for tumor growth inhibition
|
|
CA3081602A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
CA3081770A1
(en)
|
2017-11-29 |
2019-06-06 |
Csl Limited |
Method of treating or preventing ischemia-reperfusion injury
|
|
WO2019106126A1
(en)
|
2017-12-01 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mdm2 modulators for the diagnosis and treatment of liposarcoma
|
|
EP3720950B1
(en)
|
2017-12-05 |
2025-09-03 |
Celyad S.A. |
Reducing fratricide of immune cells expressing nkg2d-based receptors
|
|
US12173316B2
(en)
|
2017-12-05 |
2024-12-24 |
Celyad S.A |
Compositions and methods for improving persistence of cells for adoptive transfer
|
|
US20200377571A1
(en)
|
2017-12-08 |
2020-12-03 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
WO2019121872A1
(en)
|
2017-12-20 |
2019-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of liver cancer
|
|
WO2019129136A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
|
CN109970857B
(zh)
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
|
WO2019129054A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
三链抗体、其制备方法及其用途
|
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
SG11202004158QA
(en)
|
2017-12-28 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against tigit
|
|
CN108218990B
(zh)
|
2017-12-29 |
2021-03-02 |
南京优迈生物科技有限公司 |
分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
WO2019140116A2
(en)
|
2018-01-10 |
2019-07-18 |
Rubius Therapeutics, Inc. |
Amplifiable rnas for therapeutic cell systems
|
|
US11713353B2
(en)
|
2018-01-15 |
2023-08-01 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against PD-1
|
|
US11965191B2
(en)
|
2018-01-18 |
2024-04-23 |
California Institute Of Technology |
Programmable protein circuits in living cells
|
|
US10899823B2
(en)
|
2018-01-18 |
2021-01-26 |
California Institute Of Technology |
Programmable protein circuits in living cells
|
|
JP2021512151A
(ja)
|
2018-01-23 |
2021-05-13 |
ネクストキュア インコーポレイテッド |
Ｂ７−ｈ４抗体およびその使用方法
|
|
WO2019145413A1
(en)
|
2018-01-25 |
2019-08-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antagonists of il-33 for use in methods for preventing ischemia reperfusion injury in an organ
|
|
US20200354424A1
(en)
|
2018-01-26 |
2020-11-12 |
Orionis Biosciences, Inc. |
Xcr1 binding agents and uses thereof
|
|
WO2019152660A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
WO2019152895A1
(en)
|
2018-02-01 |
2019-08-08 |
Memorial Sloan Kettering Cancer Center |
Antibodies to galectin-3 and methods of use thereof
|
|
KR102877915B1
(ko)
|
2018-02-05 |
2025-10-29 |
오리오니스 바이오사이언시즈 인코포레이티드 |
섬유아세포 결합제 및 이의 용도
|
|
WO2019151865A1
(en)
|
2018-02-05 |
2019-08-08 |
Stichting Vu |
Inverse agonistic anti-us28 antibodies
|
|
AU2019217584B2
(en)
|
2018-02-06 |
2025-08-14 |
Ablynx Nv |
Methods of treating initial episode of TTP with immunoglobulin single variable domains
|
|
US11802303B2
(en)
|
2018-02-07 |
2023-10-31 |
Georgia Tech Research Corporation |
Methods for multiplexed cell isolation using DNA gates
|
|
WO2019156566A1
(en)
|
2018-02-12 |
2019-08-15 |
Umc Utrecht Holding B.V. |
Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
|
|
WO2019155041A1
(en)
|
2018-02-12 |
2019-08-15 |
Vib Vzw |
Gβγ COMPLEX ANTIBODIES AND USES THEREOF
|
|
EP3752194A4
(en)
|
2018-02-13 |
2022-03-16 |
Checkmate Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
|
|
WO2019158512A1
(en)
|
2018-02-13 |
2019-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prognosis and the treatment of glioblastoma
|
|
WO2019169229A1
(en)
|
2018-03-01 |
2019-09-06 |
Nextcure, Inc. |
Klrg1 binding compositions and methods of use thereof
|
|
US11858960B2
(en)
|
2018-03-01 |
2024-01-02 |
Vrije Universiteit Brussel |
Human PD-L1-binding immunoglobulins
|
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
|
AU2019233603B2
(en)
|
2018-03-13 |
2025-06-26 |
Smivet B.V. |
Single domain antibodies binding to tetanus neurotoxin
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
NZ782442A
(en)
|
2018-03-14 |
2022-01-28 |
Surface Oncology Inc |
Antibodies that bind cd39 and uses thereof
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US11661452B2
(en)
|
2018-03-20 |
2023-05-30 |
WuXi Biologics Ireland Limited |
Anti-lag-3 antibody polypeptide
|
|
EP3768725A4
(en)
|
2018-03-20 |
2021-06-02 |
Wuxi Biologics Ireland Limited |
NEW ANTI-TIM-3 ANTIBODIES
|
|
KR102879521B1
(ko)
|
2018-03-22 |
2025-11-03 |
서피스 온콜로지, 엘엘씨 |
항-il-27 항체 및 이의 용도
|
|
US12281160B2
(en)
|
2018-03-23 |
2025-04-22 |
Csl Limited |
Method of treating asthma
|
|
JP7390729B2
(ja)
|
2018-03-23 |
2023-12-04 |
ユニヴェルシテ リブル ドゥ ブリュッセル |
Ｗｎｔシグナル伝達アゴニスト分子
|
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
|
JP2021519093A
(ja)
|
2018-03-27 |
2021-08-10 |
ユーエムシー ユトレヒト ホールディング ビー．ブイ． |
微小血管血栓症の処置のための標的化血栓溶解
|
|
US20210047696A1
(en)
|
2018-03-28 |
2021-02-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
EP3774917B1
(en)
|
2018-03-30 |
2025-10-29 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against lag-3 and uses thereof
|
|
WO2019193375A1
(en)
|
2018-04-04 |
2019-10-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fzd7 inhibitors for the treatment of retinal neovascularization
|
|
IL319506A
(en)
|
2018-04-09 |
2025-05-01 |
Checkmate Pharmaceuticals Inc |
Packaging of oligonucleotides in virus-like particles
|
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
JP2021521445A
(ja)
|
2018-04-13 |
2021-08-26 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前立腺癌又は乳癌を患っている患者の転帰を予測するための及び処置のための方法
|
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
US12048745B2
(en)
|
2018-05-01 |
2024-07-30 |
Augusta University Research Institute, Inc. |
Methods for detecting and reversing immune therapy resistance
|
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
KR20240056644A
(ko)
|
2018-05-10 |
2024-04-30 |
주식회사 뉴라클사이언스 |
서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
|
|
US20190345261A1
(en)
|
2018-05-10 |
2019-11-14 |
Sensei Biotherapeutics, Inc. |
Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
|
|
BR112020023330A2
(pt)
|
2018-05-14 |
2021-04-20 |
Harpoon Therapeutics, Inc. |
porção de ligação para ativação condicional de moléculas de imunoglobulina
|
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
|
WO2019226617A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
WO2019226050A2
(en)
|
2018-05-24 |
2019-11-28 |
Wageningen Universiteit |
Novel viral anti-infective reagents
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
US12404320B2
(en)
|
2018-05-31 |
2025-09-02 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
|
|
UY38251A
(es)
|
2018-06-01 |
2019-12-31 |
Novartis Ag |
Moléculas de unión contra bcma y usos de las mismas
|
|
US12460012B2
(en)
|
2018-06-04 |
2025-11-04 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
|
|
WO2019234099A1
(en)
|
2018-06-06 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
|
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
MX2020013443A
(es)
|
2018-06-13 |
2021-02-26 |
Novartis Ag |
Receptores de antigeno quimerico de bcma y usos de los mismos.
|
|
WO2019241685A1
(en)
|
2018-06-14 |
2019-12-19 |
Bluebird Bio, Inc. |
Cd79a chimeric antigen receptors
|
|
US12091438B2
(en)
|
2018-06-18 |
2024-09-17 |
Anwita Biosciences, Inc. |
Anti-mesothelin constructs and uses thereof
|
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
|
WO2020006266A1
(en)
|
2018-06-28 |
2020-01-02 |
Alexion Pharmaceuticals, Inc. |
Methods of producing anti-c5 antibodies
|
|
CN112351998B
(zh)
|
2018-06-29 |
2022-07-22 |
苏州智核生物医药科技有限公司 |
Pd-l1结合多肽及其用途
|
|
CN118754985A
(zh)
|
2018-06-29 |
2024-10-11 |
爱必泰生物有限公司 |
抗l1cam抗体及其用途
|
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
MX2021000165A
(es)
|
2018-07-11 |
2021-05-28 |
Actym Therapeutics Inc |
Cepas bacterianas inmunoestimuladoras modificadas y usos de las mismas.
|
|
EP3820515A1
(en)
|
2018-07-11 |
2021-05-19 |
Celgene Corporation |
Uses of anti-bcma chimeric antigen receptors
|
|
WO2020016160A1
(en)
|
2018-07-16 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat neurological diseases
|
|
WO2020016377A1
(en)
|
2018-07-19 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination for treating cancer
|
|
AU2019306165A1
(en)
|
2018-07-20 |
2021-02-25 |
Pierre Fabre Medicament |
Receptor for vista
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
ES2738926A1
(es)
|
2018-07-26 |
2020-01-27 |
Univ Zaragoza |
Granulisina, metodo de obtencion y usos
|
|
WO2020028909A1
(en)
|
2018-08-03 |
2020-02-06 |
Brown University |
Oral formulations with increased uptake
|
|
WO2020033923A1
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
|
EP3833442A2
(en)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antibodies that bind cd277 and uses thereof
|
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
|
EP3837277A4
(en)
|
2018-08-17 |
2022-05-11 |
Icahn School of Medicine at Mount Sinai |
RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
|
|
US11453893B2
(en)
|
2018-08-30 |
2022-09-27 |
California Institute Of Technology |
RNA-based delivery systems with levels of control
|
|
US20210171909A1
(en)
|
2018-08-31 |
2021-06-10 |
Novartis Ag |
Methods of making chimeric antigen receptor?expressing cells
|
|
WO2020047320A1
(en)
|
2018-08-31 |
2020-03-05 |
California Institute Of Technology |
Synthetic protein circuits detecting signal transducer activity
|
|
DK3844267T3
(da)
|
2018-08-31 |
2025-09-22 |
Novartis Ag |
Fremgangsmåder til fremstilling af kimære antigenreceptorudtrykkende celler
|
|
WO2020048454A1
(zh)
|
2018-09-04 |
2020-03-12 |
南京优迈生物科技有限公司 |
融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用
|
|
GB201814451D0
(en)
|
2018-09-05 |
2018-10-17 |
Valerie Nicholas Carl Kristoffer |
Methods
|
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
|
JP7548587B2
(ja)
|
2018-09-07 |
2024-09-10 |
アイタブメッド （エイチケイ） リミテッド |
二重特異性抗原結合タンパク質及びその使用
|
|
US12365705B2
(en)
|
2018-09-11 |
2025-07-22 |
Nanotag Biotechnologies Gmbh |
Epitope tags recognized by specific binders
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
EP3856772A1
(en)
|
2018-09-25 |
2021-08-04 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
|
IL281683B2
(en)
|
2018-09-25 |
2023-04-01 |
Harpoon Therapeutics Inc |
dll3 binding proteins and methods of use
|
|
US20220242957A1
(en)
|
2018-09-27 |
2022-08-04 |
Marengo Therapeutics, Inc. |
Csf1r/ccr2 multispecific antibodies
|
|
CN112771071A
(zh)
|
2018-09-28 |
2021-05-07 |
麻省理工学院 |
胶原蛋白定位的免疫调节分子及其方法
|
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
|
CA3113575A1
(en)
|
2018-10-03 |
2020-04-09 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
|
|
WO2020070288A1
(en)
|
2018-10-05 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
|
TW202035445A
(zh)
|
2018-10-10 |
2020-10-01 |
美商帝洛斯療法股份有限公司 |
抗lap抗體變異體及其用途
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
WO2020080941A1
(en)
|
2018-10-16 |
2020-04-23 |
Umc Utrecht Holding B.V. |
Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
|
|
EP3870600A1
(en)
|
2018-10-24 |
2021-09-01 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
BR112021008063A2
(pt)
|
2018-10-30 |
2021-08-10 |
Alexion Pharmaceuticals, Inc. |
dosagem subcutânea e administração de anticorpos anti-c 5 para tratamento de hemoglobinúria paroxística noturna (pnh)
|
|
WO2020089273A1
(en)
|
2018-10-31 |
2020-05-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating t-helper type 2 mediated disease
|
|
US12410225B2
(en)
|
2018-11-08 |
2025-09-09 |
Orionis Biosciences, Inc |
Modulation of dendritic cell lineages
|
|
US11046769B2
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
GB201818477D0
(en)
|
2018-11-13 |
2018-12-26 |
Emstopa Ltd |
Tissue plasminogen activator antibodies and method of use thereof
|
|
US12422441B2
(en)
|
2018-12-07 |
2025-09-23 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
|
WO2020120644A1
(en)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New anti tau svqivykpv epitope single domain antibody
|
|
EP3894440A4
(en)
|
2018-12-13 |
2022-09-07 |
Surface Oncology, Inc. |
ANTI-IL-27 ANTIBODIES AND USES THEREOF
|
|
KR20210106483A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
Mdm2 억제제를 위한 확장된 저용량 요법
|
|
AU2019407814B2
(en)
|
2018-12-21 |
2026-02-12 |
Boehringer Ingelheim International Gmbh |
Bifunctional anti-PD-1/IL-7 molecule
|
|
WO2020130838A2
(en)
|
2018-12-21 |
2020-06-25 |
Qvq Holding B.V. |
Antibodies for preventing or treating candidiasis
|
|
CN113574067A
(zh)
|
2018-12-21 |
2021-10-29 |
Ose免疫疗法公司 |
双功能抗PD-1/SIRPα分子
|
|
CN113573782B
(zh)
|
2018-12-21 |
2025-12-16 |
Ose免疫疗法公司 |
针对人pd-1的双功能分子
|
|
SG11202104217QA
(en)
|
2019-01-02 |
2021-05-28 |
Neuracle Science Co Ltd |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
WO2020141199A1
(en)
|
2019-01-03 |
2020-07-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
|
|
WO2020144164A1
(en)
|
2019-01-07 |
2020-07-16 |
Bactolife Aps |
Pathogen binding proteins
|
|
WO2020146627A1
(en)
|
2019-01-10 |
2020-07-16 |
California Institute Of Technology |
A synthetic system for tunable thresholding of protein signals
|
|
CN113508129B
(zh)
|
2019-01-15 |
2025-02-18 |
法国国家健康和医学研究院 |
突变的白介素-34(il-34)多肽及其在治疗中的用途
|
|
WO2020148349A1
(en)
|
2019-01-16 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Variants of erythroferrone and their use
|
|
AU2020208397A1
(en)
|
2019-01-16 |
2021-08-12 |
Compass Therapeutics Llc |
Formulations of antibodies that bind human CD137 and uses thereof
|
|
TWI756621B
(zh)
|
2019-01-25 |
2022-03-01 |
大陸商信達生物製藥（蘇州）有限公司 |
新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
|
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
CN113661175A
(zh)
|
2019-02-15 |
2021-11-16 |
整体分子公司 |
包含共同轻链的抗体及其用途
|
|
CA3129834A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Claudin 6 antibodies and uses thereof
|
|
JP7737306B2
(ja)
|
2019-02-21 |
2025-09-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
|
WO2020172605A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
WO2020169707A1
(en)
|
2019-02-21 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Foxo1 inhibitor for use in the treatment of latent virus infection
|
|
SG11202109056TA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CN114126714A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
WO2020176497A1
(en)
|
2019-02-26 |
2020-09-03 |
Rgenix, Inc. |
High-affinity anti-mertk antibodies and uses thereof
|
|
WO2020180534A1
(en)
|
2019-03-01 |
2020-09-10 |
President And Fellows Of Harvard College |
Methods and compositions for protein delivery
|
|
EP4378485A3
(en)
|
2019-03-08 |
2024-08-28 |
LinXis B.V. |
Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
|
|
CN113966397A
(zh)
|
2019-03-08 |
2022-01-21 |
黑曜石疗法公司 |
人碳酸酐酶2组合物和用于可调调节的方法
|
|
WO2020198731A2
(en)
|
2019-03-28 |
2020-10-01 |
Danisco Us Inc |
Engineered antibodies
|
|
WO2020193740A1
(en)
|
2019-03-28 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
|
MX2021011830A
(es)
|
2019-03-29 |
2022-01-24 |
Atarga Llc |
Anticuerpo anti fgf23.
|
|
WO2020205827A1
(en)
|
2019-04-01 |
2020-10-08 |
Rush University Medical Center |
Reagents and assays using modified integrin domains
|
|
CN113939273A
(zh)
|
2019-04-03 |
2022-01-14 |
哈佛大学校长及研究员协会 |
用于药物递送的离子液体
|
|
EP3947472A4
(en)
|
2019-04-04 |
2023-02-22 |
Vanderbilt University |
THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF LUNG CANCER
|
|
WO2020208082A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating cmv related diseases
|
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
KR20240160655A
(ko)
|
2019-04-29 |
2024-11-11 |
콘포 테라퓨틱스 엔.브이. |
트랜스맴브레인 단백질, 특히 gpcr과 함께 사용하기 위한 스크리닝 방법 및 검정
|
|
WO2020221888A1
(en)
|
2019-04-30 |
2020-11-05 |
Vib Vzw |
Cystic fibrosis transmembrane conductance regulator stabilizing agents
|
|
EP3969908A1
(en)
|
2019-05-13 |
2022-03-23 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
US12516128B2
(en)
|
2019-05-14 |
2026-01-06 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
JP2022533591A
(ja)
|
2019-05-14 |
2022-07-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
リンホトキシンアルファ遮断剤によりターゲットされた制御性ｔ細胞及びその使用
|
|
US20220227859A1
(en)
|
2019-05-16 |
2022-07-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat type 2 inflammation or mast-cell dependent disease
|
|
US12037378B2
(en)
|
2019-05-21 |
2024-07-16 |
Novartis Ag |
Variant CD58 domains and uses thereof
|
|
KR20220010743A
(ko)
|
2019-05-21 |
2022-01-26 |
노파르티스 아게 |
Bcma에 대한 삼중특이적 결합 분자 및 이의 용도
|
|
CU20210096A7
(es)
|
2019-05-21 |
2022-06-06 |
Novartis Ag |
Moléculas de unión a cd19
|
|
WO2020238730A1
(zh)
|
2019-05-24 |
2020-12-03 |
三优生物医药(上海)有限公司 |
新型cldn18.2结合分子
|
|
US20220220197A1
(en)
|
2019-05-28 |
2022-07-14 |
Vib Vzw |
Cancer Treatment by Targeting Plexins in the Immune Compartment
|
|
US12472254B2
(en)
|
2019-05-28 |
2025-11-18 |
Vib Vzw |
CD8+ T-cells lacking plexins and their application in cancer treatment
|
|
GB2584441A
(en)
|
2019-06-03 |
2020-12-09 |
Fenomark Diagnostics Ab |
Medical uses, methods and uses
|
|
JP7554781B2
(ja)
|
2019-06-04 |
2024-09-20 |
普米斯生物技術（珠海）有限公司 |
抗ｃｅａｃａｍ５モノクローナル抗体およびその調製方法およびその使用
|
|
JP7520893B2
(ja)
|
2019-06-12 |
2024-07-23 |
ノバルティス アーゲー |
ナトリウム利尿ペプチド受容体１抗体及び使用方法
|
|
WO2020257289A2
(en)
|
2019-06-17 |
2020-12-24 |
Visterra, Inc. |
Humanized antibody molecules to cd138 and uses thereof
|
|
WO2020254619A1
(en)
|
2019-06-20 |
2020-12-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- protease nexin-1 conformational single domain antibodies and uses thereof
|
|
EP3986931A1
(en)
|
2019-06-21 |
2022-04-27 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
|
CN114555643B
(zh)
|
2019-06-21 |
2025-02-18 |
索瑞索制药公司 |
组合物
|
|
AU2020294980A1
(en)
|
2019-06-21 |
2022-02-17 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質－金属水酸化物錯体およびその方法
|
|
WO2021000886A1
(zh)
|
2019-07-01 |
2021-01-07 |
苏州康宁杰瑞生物科技有限公司 |
百日咳毒素结合蛋白
|
|
WO2021001539A1
(en)
|
2019-07-04 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy to detect and treat eosinophilic fasciitis
|
|
JP7757271B2
(ja)
|
2019-07-15 |
2025-10-21 |
インターベット インターナショナル ベー． フェー． |
イヌｃｔｌａ－４に対するイヌ化抗体
|
|
TWI889694B
(zh)
|
2019-07-26 |
2025-07-11 |
美商威特拉公司 |
介白素-2藥劑及其用途
|
|
WO2021025556A1
(en)
|
2019-08-05 |
2021-02-11 |
Stichting Vu |
Identification and elimination of hcmv-infected cells
|
|
EP4021486A1
(en)
|
2019-08-30 |
2022-07-06 |
Agenus Inc. |
Anti-cd96 antibodies and methods of use thereof
|
|
KR20220057563A
(ko)
|
2019-09-04 |
2022-05-09 |
제넨테크, 인크. |
Cd8 결합제 및 이의 용도
|
|
EP4025712A1
(en)
|
2019-09-05 |
2022-07-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Method of treatment and pronostic of acute myeloid leukemia
|
|
US20220348937A1
(en)
|
2019-09-06 |
2022-11-03 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
US11655303B2
(en)
|
2019-09-16 |
2023-05-23 |
Surface Oncology, Inc. |
Anti-CD39 antibody compositions and methods
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
AU2020353672A1
(en)
|
2019-09-25 |
2022-03-31 |
Surface Oncology, LLC |
Anti-IL-27 antibodies and uses thereof
|
|
TW202126295A
(zh)
|
2019-09-27 |
2021-07-16 |
大陸商江蘇挪貝肽醫藥科技有限公司 |
一種治療心境障礙的方法
|
|
US20220290151A1
(en)
|
2019-09-27 |
2022-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of müllerian inhibiting substance inhibitors for treating cancer
|
|
TWI878355B
(zh)
|
2019-10-02 |
2025-04-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
|
EP3799881A1
(en)
|
2019-10-04 |
2021-04-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Single domain antibodies specifically binding globo - series glycans
|
|
TW202128166A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
組合療法
|
|
AU2020370832A1
(en)
|
2019-10-21 |
2022-05-19 |
Novartis Ag |
TIM-3 inhibitors and uses thereof
|
|
US20220380456A1
(en)
|
2019-10-21 |
2022-12-01 |
Vib Vzw |
Nanodisc-specific antigen-binding chimeric proteins
|
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
|
WO2021086953A1
(en)
|
2019-10-28 |
2021-05-06 |
Georgia Tech Research Corporation |
Compositions and methods for prophylaxis of hiv
|
|
WO2021086948A1
(en)
|
2019-10-28 |
2021-05-06 |
Georgia Tech Research Corporation |
Mrna-encoded antibodies for contraception
|
|
JP2022554351A
(ja)
|
2019-11-05 |
2022-12-28 |
セルジーン コーポレイション |
抗ｂｃｍａキメラ抗原受容体の使用法
|
|
IL292879B2
(en)
|
2019-11-11 |
2025-08-01 |
Ibi Ag Innovative Bio Insecticides Ltd |
Nanoantibodies for insect control and their uses
|
|
EP4613276A3
(en)
|
2019-11-12 |
2025-12-17 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
|
|
WO2021102084A1
(en)
|
2019-11-22 |
2021-05-27 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
WO2021105438A1
(en)
|
2019-11-27 |
2021-06-03 |
Vib Vzw |
Positive allosteric modulators of the calcium-sensing receptor
|
|
WO2021105391A1
(en)
|
2019-11-27 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination comprising nupr1 inhibitors to treat cancer
|
|
WO2021105384A1
(en)
|
2019-11-27 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Targeting the nls region of nupr1 protein to treat cancer
|
|
WO2021110990A1
(en)
|
2019-12-05 |
2021-06-10 |
Ose Immunotherapeutics |
Anti-clec-1a antibodies and antigen-binding fragment thereof
|
|
PH12022551214A1
(en)
|
2019-12-06 |
2023-10-09 |
Ablynx Nv |
Polypeptides comprising immunoglobulin single variable domains targeting tnf# and il-23
|
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
|
WO2021110817A1
(en)
|
2019-12-06 |
2021-06-10 |
Ablynx Nv |
Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
|
|
US20210188965A1
(en)
|
2019-12-09 |
2021-06-24 |
Ablynx N.V. |
Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
|
|
EP4072682A1
(en)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antibodies having specificity to her4 and uses thereof
|
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
|
WO2021122866A1
(en)
|
2019-12-17 |
2021-06-24 |
Ose Immunotherapeutics |
Bifunctional molecules comprising an il-7 variant
|
|
US20240027467A1
(en)
|
2019-12-20 |
2024-01-25 |
Vib Vzw |
Nanobody Exchange Chromatography
|
|
JP2023507190A
(ja)
|
2019-12-20 |
2023-02-21 |
ノバルティス アーゲー |
増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
|
|
EP4076525A4
(en)
|
2019-12-20 |
2024-05-01 |
Momenta Pharmaceuticals, Inc. |
ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1
|
|
EP4077385A4
(en)
|
2019-12-20 |
2023-12-13 |
Hudson Institute of Medical Research |
CXCL10 BINDING PROTEINS AND THEIR USES
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
EP4087607A1
(en)
|
2020-01-06 |
2022-11-16 |
Vaccinex, Inc. |
Anti-ccr8 antibodies and uses thereof
|
|
WO2021140205A1
(en)
|
2020-01-10 |
2021-07-15 |
Confo Therapeutics N.V. |
Methods for generating antibodies and antibody fragments and libraries comprising same
|
|
TWI869528B
(zh)
|
2020-01-13 |
2025-01-11 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
|
MX2022008845A
(es)
|
2020-01-17 |
2022-08-10 |
Univ Gent |
Anticuerpos de dominio unico de inmunoglobulina para la entrega de vacunas a traves de la mucosa.
|
|
EP4090335A1
(en)
|
2020-01-17 |
2022-11-23 |
Novartis AG |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
WO2021156490A2
(en)
|
2020-02-06 |
2021-08-12 |
Vib Vzw |
Corona virus binders
|
|
EP4104187A1
(en)
|
2020-02-14 |
2022-12-21 |
Novartis AG |
Method of predicting response to chimeric antigen receptor therapy
|
|
AU2021224851A1
(en)
|
2020-02-21 |
2022-09-15 |
Harpoon Therapeutics, Inc. |
FLT3 binding proteins and methods of use
|
|
WO2021170540A1
(en)
|
2020-02-25 |
2021-09-02 |
Vib Vzw |
Leucine-rich repeat kinase 2 allosteric modulators
|
|
WO2021173674A1
(en)
|
2020-02-26 |
2021-09-02 |
A2 Biotherapeutics, Inc. |
Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
|
|
AU2021225949A1
(en)
|
2020-02-27 |
2022-09-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
TW202146441A
(zh)
|
2020-02-27 |
2021-12-16 |
瑞士商諾華公司 |
製備表現嵌合抗原受體的細胞之方法
|
|
EP4117716A2
(en)
|
2020-03-10 |
2023-01-18 |
Massachusetts Institute of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
|
CN115485295A
(zh)
|
2020-03-10 |
2022-12-16 |
麻省理工学院 |
NPM1c阳性癌症的免疫疗法的组合物和方法
|
|
DE102020111571A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
|
AU2021236302A1
(en)
|
2020-03-12 |
2022-10-20 |
Immune-Onc Therapeutics, Inc. |
Novel anti-LILRB4 antibodies and derivative products
|
|
TWI873311B
(zh)
|
2020-03-13 |
2025-02-21 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Ｐｖｒｉｇ結合蛋白及其醫藥用途
|
|
EP4121756A1
(en)
|
2020-03-20 |
2023-01-25 |
GlaxoSmithKline Intellectual Property Development Limited |
Method for detecting polysorbates
|
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
|
EP4126241A1
(en)
|
2020-03-27 |
2023-02-08 |
Novartis AG |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
|
JP2023519967A
(ja)
|
2020-03-30 |
2023-05-15 |
アブリンクス・エヌ・フェー |
多価免疫グロブリン単一可変ドメインの製造及び精製のための方法
|
|
CN113461817B
(zh)
|
2020-03-31 |
2025-04-18 |
苏州泽璟生物制药股份有限公司 |
一种抗人cd47抗体及其抗原结合片段、制备方法和应用
|
|
HUE069576T2
(hu)
|
2020-03-31 |
2025-03-28 |
Biotalys NV |
Gombaellenes polipeptidek
|
|
AU2021248643A1
(en)
|
2020-04-03 |
2022-10-27 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
|
CA3180222A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
EP4135837A1
(en)
|
2020-04-16 |
2023-02-22 |
Assistance Publique, Hopitaux De Paris |
Methods for treating a complement mediated disorder caused by viruses
|
|
JP2023523600A
(ja)
|
2020-04-22 |
2023-06-06 |
マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド |
ヒトプログラム細胞死リガンド１（ｐｄ－ｌ１）を標的とする単一可変ドメイン抗体およびその誘導体
|
|
GB2612450A
(en)
|
2020-04-24 |
2023-05-03 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
WO2021222546A1
(en)
|
2020-05-01 |
2021-11-04 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Compositions and methods for identifying nanobodies and nanobody affinities
|
|
JP2023525695A
(ja)
|
2020-05-04 |
2023-06-19 |
イミュノライゾン リミテッド |
前駆体三重特異性抗体構築物及びその使用方法
|
|
EP4149558A1
(en)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
|
WO2021229104A1
(en)
|
2020-05-15 |
2021-11-18 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
|
PH12022553153A1
(en)
|
2020-05-19 |
2024-02-26 |
Boehringer Ingelheim Int |
Binding molecules for the treatment of cancer
|
|
WO2021233962A1
(en)
|
2020-05-19 |
2021-11-25 |
Institut Curie |
Methods for the diagnosis and treatment of cytokine release syndrome
|
|
EP3916088A1
(en)
|
2020-05-28 |
2021-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins comprising the sars-cov-2 3clpro catalytic domain and their uses for screening anti-sars-cov-2 agents
|
|
CA3180060A1
(en)
|
2020-05-29 |
2021-12-02 |
Zongmin ZHAO |
Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
|
|
CN111647077B
(zh)
|
2020-06-02 |
2021-02-09 |
深圳市因诺赛生物科技有限公司 |
新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用
|
|
JP7776448B2
(ja)
|
2020-06-02 |
2025-11-26 |
アーカス バイオサイエンシズ インコーポレイティド |
Ｔｉｇｉｔに対する抗体
|
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
CA3187267A1
(en)
|
2020-06-17 |
2021-12-23 |
Janssen Biotech, Inc. |
Materials and methods for the manufacture of pluripotent stem cells
|
|
US20230218608A1
(en)
|
2020-06-18 |
2023-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
|
MX2022016591A
(es)
|
2020-06-24 |
2023-04-20 |
Visterra Inc |
Moléculas de anticuerpo contra april y usos de las mismas.
|
|
JP2023532726A
(ja)
|
2020-06-29 |
2023-07-31 |
インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） |
抗プロテインｓシングルドメイン抗体及びそれを含むポリペプチド
|
|
US12077576B2
(en)
|
2020-07-02 |
2024-09-03 |
Trustees Of Tufts College |
VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
|
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
|
WO2022002233A1
(zh)
|
2020-07-03 |
2022-01-06 |
苏州康宁杰瑞生物科技有限公司 |
凝血因子xi(fxi)结合蛋白
|
|
EP4182025A1
(en)
|
2020-07-16 |
2023-05-24 |
Novartis AG |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
CN113956357B
(zh)
|
2020-07-21 |
2024-02-20 |
苏州智核生物医药科技有限公司 |
Cd8结合多肽及其用途
|
|
TW202216760A
(zh)
|
2020-07-23 |
2022-05-01 |
愛爾蘭商歐薩爾普羅席納有限公司 |
抗類澱粉β (ABETA)抗體
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
EP4189060A1
(en)
|
2020-07-31 |
2023-06-07 |
Biotalys NV |
Expression host
|
|
KR20230062833A
(ko)
|
2020-08-10 |
2023-05-09 |
얀센 바이오테크 인코포레이티드 |
생물공학적 바이러스 특이적 림프구 생산을 위한 재료 및 방법
|
|
CA3191433A1
(en)
|
2020-08-12 |
2022-02-17 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
|
|
US20220056411A1
(en)
|
2020-08-21 |
2022-02-24 |
Immatics US, Inc. |
Methods for isolating cd8+ selected t cells
|
|
CN116249718A
(zh)
|
2020-08-26 |
2023-06-09 |
马伦戈治疗公司 |
结合至钙网蛋白的多功能性分子及其用途
|
|
WO2022046922A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
JP2023540248A
(ja)
|
2020-08-26 |
2023-09-22 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
JP2023541455A
(ja)
|
2020-09-14 |
2023-10-02 |
ブイオーアール バイオファーマ インコーポレーテッド |
Ｃｄ３３に対する単一ドメイン抗体
|
|
WO2022060806A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
|
|
EP4214235A1
(en)
|
2020-09-16 |
2023-07-26 |
LinXis B.V. |
Internalizing binding molecules
|
|
WO2022063957A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Biomarker for anti-tumor therapy
|
|
CA3196737A1
(en)
|
2020-09-24 |
2022-03-31 |
Massimiliano Mazzone |
Combination of p2y6 inhibitors and immune checkpoint inhibitors
|
|
CA3195687A1
(en)
|
2020-09-25 |
2022-03-31 |
Ablynx Nv |
Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
|
|
TW202229350A
(zh)
|
2020-10-14 |
2022-08-01 |
美商維里迪恩醫療股份有限公司 |
用於治療甲狀腺眼病之組合物及方法
|
|
US20230416346A1
(en)
|
2020-10-21 |
2023-12-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
C-terminal sparc fragments for treating cancer
|
|
JP2023546229A
(ja)
|
2020-10-21 |
2023-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
眼の疾患の処置のためのアゴニスト性ＴｒｋＢ結合分子
|
|
EP4241278A2
(en)
|
2020-11-04 |
2023-09-13 |
Celgene Corporation |
Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
|
|
KR20230104651A
(ko)
|
2020-11-06 |
2023-07-10 |
노파르티스 아게 |
Cd19 결합 분자 및 이의 용도
|
|
US20250215081A1
(en)
|
2020-11-06 |
2025-07-03 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
CN112480248B
(zh)
|
2020-11-24 |
2023-05-05 |
三优生物医药(上海)有限公司 |
与cld18a2特异性结合的分子
|
|
WO2022117572A2
(en)
|
2020-12-02 |
2022-06-09 |
Oncurious Nv |
An ltbr agonist in combination therapy against cancer
|
|
WO2022117569A1
(en)
|
2020-12-02 |
2022-06-09 |
Oncurious Nv |
A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
JP2024502708A
(ja)
|
2020-12-04 |
2024-01-23 |
ビステラ， インコーポレイテッド |
インターロイキン－２作用物質を使用する方法
|
|
US20240016936A1
(en)
|
2020-12-04 |
2024-01-18 |
Celgene Corporation |
Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
|
|
EP4259661A1
(en)
|
2020-12-14 |
2023-10-18 |
Novartis AG |
Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
|
|
US20240067727A1
(en)
|
2020-12-17 |
2024-02-29 |
Ose Immunotherapeutics |
Bifunctional anti-pd1/il-7 molecules
|
|
IL303783A
(en)
|
2020-12-18 |
2023-08-01 |
Sanofi Sa |
Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
|
|
IL303740A
(en)
|
2020-12-18 |
2023-08-01 |
Sanofi Sa |
T cell recruiting polypeptides based on tcr alpha/beta reactivity
|
|
US11897951B2
(en)
|
2020-12-18 |
2024-02-13 |
Ablynx N.V. |
Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
|
|
GB202020502D0
(en)
|
2020-12-23 |
2021-02-03 |
Vib Vzw |
Antibody composistion for treatment of corona virus infection
|
|
CA3206125A1
(en)
|
2020-12-24 |
2022-06-30 |
Vib Vzw |
Murine cross-reactive human ccr8 binders
|
|
US20240076391A1
(en)
|
2020-12-24 |
2024-03-07 |
Oncurious Nv |
Human ccr8 binders
|
|
CA3206124A1
(en)
|
2020-12-24 |
2022-06-30 |
Vib Vzw |
Non-blocking human ccr8 binders
|
|
CA3208934A1
(en)
|
2021-01-20 |
2022-07-28 |
Visterra, Inc. |
Interleukin-2 mutants and uses thereof
|
|
GB2603166A
(en)
|
2021-01-29 |
2022-08-03 |
Thelper As |
Therapeutic and Diagnostic Agents and Uses Thereof
|
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
CN119487066A
(zh)
|
2021-02-01 |
2025-02-18 |
羿尊生物医药（浙江）有限公司 |
一种靶向蛋白降解系统及其应用
|
|
CN117794566A
(zh)
|
2021-02-05 |
2024-03-29 |
Vib研究所 |
沙贝病毒结合剂
|
|
IL304929A
(en)
|
2021-02-05 |
2023-10-01 |
Vib Vzw [Be/Be |
Sarbevirus binders
|
|
CA3206844A1
(en)
|
2021-02-05 |
2022-08-11 |
John Li |
Il-15 fusion proteins and methods of making and using same
|
|
WO2022171777A1
(en)
|
2021-02-12 |
2022-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for prognosis and treating a patient suffering from cancer
|
|
US20240130999A1
(en)
|
2021-02-17 |
2024-04-25 |
Vib Vzw |
Inhibition of SLC4A4 in the Treatment of Cancer
|
|
EP4296282A4
(en)
|
2021-02-19 |
2025-02-26 |
SHAPERON Inc. |
SINGLE DOMAIN ANTIBODIES AGAINST CD47 AND USE THEREOF
|
|
CN116917321A
(zh)
|
2021-02-19 |
2023-10-20 |
沙裴隆有限公司 |
针对pd-l1的单域抗体及其用途
|
|
IL305318A
(en)
|
2021-02-19 |
2023-10-01 |
Vib Vzw |
Cation-independent mannose-6-phosphate receptor binders
|
|
AU2022224636A1
(en)
|
2021-02-19 |
2023-09-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that neutralize sars-cov-2
|
|
CN116917322A
(zh)
|
2021-02-19 |
2023-10-20 |
沙裴隆有限公司 |
针对pd-l1及cd47的双特异性单域抗体及其用途
|
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
|
GB202104104D0
(en)
|
2021-03-24 |
2021-05-05 |
Liliumx Ltd |
Platform and method
|
|
WO2022199804A1
(en)
|
2021-03-24 |
2022-09-29 |
Vib Vzw |
Nek6 inhibition to treat als and ftd
|
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
AU2022255166A1
(en)
|
2021-04-07 |
2023-09-28 |
Century Therapeutics, Inc. |
Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
|
|
JP2024513454A
(ja)
|
2021-04-07 |
2024-03-25 |
センチュリー セラピューティクス，インコーポレイテッド |
キメラ抗原受容体細胞のための人工細胞死／リポーター系ポリペプチドの組合せおよびその使用
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
EP4320227A1
(en)
|
2021-04-07 |
2024-02-14 |
Century Therapeutics, Inc. |
Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
|
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
|
WO2022216157A1
(en)
|
2021-04-09 |
2022-10-13 |
Stichting Radboud Universiteit |
Off the shelf proximity biotinylation enzyme
|
|
US20240182571A1
(en)
|
2021-04-09 |
2024-06-06 |
Ose Immunotherapeutics |
New scaffold for bifunctional molecules with improved properties
|
|
WO2022214652A1
(en)
|
2021-04-09 |
2022-10-13 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
|
WO2022219080A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
|
WO2022219076A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve the anti-tumoral activity of macrophages
|
|
AU2022257093A1
(en)
|
2021-04-16 |
2023-11-02 |
Celgene Corporation |
T cell therapy in patients who have had prior stem cell transplant
|
|
US20220372168A1
(en)
|
2021-05-04 |
2022-11-24 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
|
KR20240005809A
(ko)
|
2021-05-07 |
2024-01-12 |
서피스 온콜로지, 엘엘씨 |
항-il-27 항체 및 이의 용도
|
|
WO2022242892A1
(en)
|
2021-05-17 |
2022-11-24 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
|
WO2022246154A2
(en)
|
2021-05-20 |
2022-11-24 |
Dianthus Therapeutics, Inc. |
Antibodies that bind to c1s and uses thereof
|
|
WO2022253910A1
(en)
|
2021-06-02 |
2022-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A new method to treat an inflammatory skin disease
|
|
AU2021451307A1
(en)
|
2021-06-16 |
2024-02-01 |
Shanghai Sinobay Biotechnology Co., Ltd. |
Antibody targeting axl protein and antigen binding fragment thereof, preparation method therefor and use thereof
|
|
WO2022263507A1
(en)
|
2021-06-17 |
2022-12-22 |
Boehringer Ingelheim International Gmbh |
Novel tri-specific binding molecules
|
|
CA3224912A1
(en)
|
2021-06-22 |
2022-12-29 |
Merck Patent Gmbh |
Vhh-based nkp30 binders
|
|
JP2024523921A
(ja)
|
2021-06-23 |
2024-07-02 |
フエー・イー・ベー・フエー・ゼツト・ウエー |
特異的バインダーの選択手段及び方法
|
|
US20230174651A1
(en)
|
2021-06-23 |
2023-06-08 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
|
CN114230665B
(zh)
|
2021-06-23 |
2024-03-22 |
苏州智核生物医药科技有限公司 |
CD8α结合多肽及其用途
|
|
CN117580865A
(zh)
|
2021-06-29 |
2024-02-20 |
山东先声生物制药有限公司 |
Cd16抗体及其应用
|
|
CA3223081A1
(en)
|
2021-07-15 |
2023-01-19 |
Samir Mitragotri |
Compositions and methods relating to cells with adhered particles
|
|
EP4378954A4
(en)
|
2021-07-30 |
2025-05-21 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
Anti-pvrig/anti-tigit bispecific antibody and application
|
|
WO2023016828A2
(en)
|
2021-07-30 |
2023-02-16 |
Vib Vzw |
Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
|
|
CN118019548A
(zh)
|
2021-08-06 |
2024-05-10 |
蒙彼利埃癌症研究所 |
用于治疗癌症的方法
|
|
EP4384219A4
(en)
|
2021-08-10 |
2025-06-18 |
Viridian Therapeutics, Inc. |
COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
|
|
WO2023023227A1
(en)
|
2021-08-20 |
2023-02-23 |
Alexion Pharmaceuticals, Inc. |
Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
|
|
WO2023023220A1
(en)
|
2021-08-20 |
2023-02-23 |
Alexion Pharmaceuticals, Inc. |
Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
|
|
CA3228641A1
(en)
|
2021-08-24 |
2023-03-02 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Fap/cd40 binding molecule and medicinal use thereof
|
|
CN117858903A
(zh)
|
2021-09-15 |
2024-04-09 |
江苏恒瑞医药股份有限公司 |
一种含抗pvrig/tigit双特异性抗体的药物组合物
|
|
WO2023041985A2
(en)
|
2021-09-15 |
2023-03-23 |
New York University In Abu Dhabicorporation |
Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof
|
|
KR20240055080A
(ko)
|
2021-09-15 |
2024-04-26 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
Pd-1에 특이적으로 결합하는 단백질 및 그의 약학적 용도
|
|
EP4401715A1
(en)
|
2021-09-17 |
2024-07-24 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
|
EP4405396A2
(en)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
US20250134952A1
(en)
|
2021-09-20 |
2025-05-01 |
Institut National de la Santé et de la Recherche Médicale |
Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
|
|
EP4413165A1
(en)
|
2021-10-06 |
2024-08-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
|
|
WO2023057601A1
(en)
|
2021-10-06 |
2023-04-13 |
Biotalys NV |
Anti-fungal polypeptides
|
|
AU2022359915A1
(en)
|
2021-10-08 |
2024-05-02 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
|
CA3234995A1
(en)
|
2021-10-14 |
2023-04-20 |
Latticon (Suzhou) Biopharmaceuticals Co., Ltd. |
Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
|
|
WO2023073099A1
(en)
|
2021-10-28 |
2023-05-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to improve phagocytosis
|
|
WO2023078906A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating acute myeloid leukemia
|
|
EP4177266A1
(en)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralizing anti-sars-cov-2 human antibodies
|
|
WO2023079137A1
(en)
|
2021-11-05 |
2023-05-11 |
Katholieke Universiteit Leuven |
Neutralizing anti-sars-cov-2 human antibodies
|
|
EP4429692A1
(en)
|
2021-11-09 |
2024-09-18 |
Ose Immunotherapeutics |
Identification of clec-1 ligand and uses thereof
|
|
WO2023086796A2
(en)
|
2021-11-09 |
2023-05-19 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
|
|
EP4180518A1
(en)
|
2021-11-12 |
2023-05-17 |
Istituto Europeo di Oncologia S.r.l. |
T cells and uses thereof
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2023089032A1
(en)
|
2021-11-19 |
2023-05-25 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
|
WO2023089159A1
(en)
|
2021-11-22 |
2023-05-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy targeting stroma/tumor cell crosstalk to treat a cancer
|
|
EP4437547A1
(en)
|
2021-11-22 |
2024-10-02 |
Ablynx N.V. |
Obtaining sequence information for target multivalent immunoglobulin single variable domains
|
|
JP2024544598A
(ja)
|
2021-11-24 |
2024-12-03 |
ノバルティス アーゲー |
アデノ随伴ウイルス形質導入の調節因子及びその使用
|
|
US20230348614A1
(en)
|
2021-11-24 |
2023-11-02 |
Visterra, Inc. |
Engineered antibody molecules to cd138 and uses thereof
|
|
US20250026842A1
(en)
|
2021-11-29 |
2025-01-23 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Modified protein or polypeptide
|
|
JP2024544057A
(ja)
|
2021-11-30 |
2024-11-27 |
蘇州康寧傑瑞生物科技有限公司 |
血栓塞栓性疾患を予防及び／又は治療する方法
|
|
CA3238574A1
(en)
|
2021-12-01 |
2023-06-08 |
Gregory Babcock |
Methods of using interleukin-2 agents
|
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
|
EP4428156A4
(en)
|
2021-12-03 |
2025-05-28 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
ANTI-BCMA NANOBODY AND USE THEREOF
|
|
AU2022409802A1
(en)
|
2021-12-15 |
2024-06-06 |
Interius Biotherapeutics, Inc. |
Pseudotyped viral particles, compositions comprising the same, and uses thereof
|
|
IL313552A
(en)
|
2021-12-17 |
2024-08-01 |
Ablynx Nv |
Polypeptides containing single immunoglobulin variable sites targeting tcraβ, cd33, and cd123
|
|
JP2025501206A
(ja)
|
2021-12-31 |
2025-01-17 |
山▲東▼先声生物制▲薬▼有限公司 |
Ｇｐｒｃ５ｄ抗体及びその応用
|
|
EP4209508A1
(en)
|
2022-01-11 |
2023-07-12 |
Centre national de la recherche scientifique |
Nanobodies for the deneddylating enzyme nedp1
|
|
US20250304664A1
(en)
|
2022-01-12 |
2025-10-02 |
Vib Vzw |
Human NTCP Binders For Therapeutic Use And Liver-Specific Targeted Delivery
|
|
GB202201137D0
(en)
|
2022-01-28 |
2022-03-16 |
Thelper As |
Therapeutic and diagnostic agents and uses thereof
|
|
IL314524A
(en)
|
2022-01-28 |
2024-09-01 |
Georgiamune Inc |
Antibodies to programmed cell death protein 1 that are agonists for PD-1
|
|
WO2023148291A1
(en)
|
2022-02-02 |
2023-08-10 |
Biotalys NV |
Methods for genome editing
|
|
WO2023148397A1
(en)
|
2022-02-07 |
2023-08-10 |
Vib Vzw |
Engineered stabilizing aglycosylated fc-regions
|
|
CN118647633A
(zh)
|
2022-02-07 |
2024-09-13 |
威斯特拉公司 |
抗独特型抗体分子及其用途
|
|
EP4476355A1
(en)
|
2022-02-11 |
2024-12-18 |
Henkel AG & Co. KGaA |
Process for the synthesis of alpha-methylene-gamma-butyrolactone
|
|
WO2023164487A1
(en)
|
2022-02-22 |
2023-08-31 |
Brown University |
Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
|
|
US20250230261A1
(en)
|
2022-03-23 |
2025-07-17 |
Bodhi Bio Llc |
Compositions and methods for antigen-specific therapy
|
|
WO2023187657A1
(en)
|
2022-03-30 |
2023-10-05 |
Novartis Ag |
Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
|
|
CA3248167A1
(en)
|
2022-04-11 |
2023-10-19 |
Vor Biopharma Inc. |
LIAISON AGENTS AND THEIR METHODS OF USE
|
|
WO2023198806A1
(en)
|
2022-04-13 |
2023-10-19 |
Ose Immunotherapeutics |
New class of molecules for selective clearance of antibody
|
|
EP4508082A1
(en)
|
2022-04-13 |
2025-02-19 |
Vib Vzw |
An ltbr agonist in combination therapy against cancer
|
|
EP4507779A1
(en)
|
2022-04-14 |
2025-02-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
|
WO2023212518A1
(en)
|
2022-04-25 |
2023-11-02 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
|
US20250276015A1
(en)
|
2022-04-28 |
2025-09-04 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Recombinant polypeptides comprising single-domain antibodies targeting herv-k subtype hml-2
|
|
WO2023215719A1
(en)
|
2022-05-02 |
2023-11-09 |
Arcus Biosciences, Inc. |
Anti-tigit antibodies and uses of the same
|
|
US20250289904A1
(en)
|
2022-05-02 |
2025-09-18 |
Umc Utrecht Holding B.V. |
Single domain antibodies for the detection of plasmin-cleaved vwf
|
|
KR20250009454A
(ko)
|
2022-05-07 |
2025-01-17 |
베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 |
릴랙신 또는 유사체의 융합 단백질 및 이의 의약적 용도
|
|
EP4522630A1
(en)
|
2022-05-10 |
2025-03-19 |
Institut National de la Santé et de la Recherche Médicale |
Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
|
|
KR20250008774A
(ko)
|
2022-05-11 |
2025-01-15 |
셀진 코포레이션 |
T 세포 요법 및 그의 생산과 관련된 방법 및 용도
|
|
CN119546628A
(zh)
|
2022-05-11 |
2025-02-28 |
再生元制药公司 |
多特异性结合分子前蛋白及其用途
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
EP4527857A1
(en)
|
2022-05-17 |
2025-03-26 |
Suzhou Transcenta Therapeutics Co., Ltd. |
Bifunctional protein, and preparation thereof and use thereof
|
|
CA3249283A1
(en)
|
2022-05-18 |
2023-11-23 |
Vib Vzw |
BINDERS OF SARBECOVIRUS SPICULE S2 SUBUNITS
|
|
US20230372395A1
(en)
|
2022-05-19 |
2023-11-23 |
Massachusetts Institute Of Technology |
Car cells targeting an inserted ligand
|
|
JP2025521122A
(ja)
|
2022-05-19 |
2025-07-08 |
シャペロン インク． |
Ｐｄ－ｌ１およびｃｄ４７に対する二重特異性ヒト化単一ドメイン抗体およびその使用
|
|
US20250345432A1
(en)
|
2022-05-25 |
2025-11-13 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
US20240025987A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
|
WO2023230128A1
(en)
|
2022-05-25 |
2023-11-30 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
|
EP4499875B1
(en)
|
2022-05-30 |
2025-03-12 |
Ose Immunotherapeutics |
Biomarkers of il7r modulator activity
|
|
AU2023280422A1
(en)
|
2022-05-31 |
2025-01-02 |
Futuregen Biopharmaceutical (Beijing) Co., Ltd. |
Anti-cd40 antibody, anti-pd-l1×cd40 bispecific antibody, and use thereof
|
|
KR20250021313A
(ko)
|
2022-06-06 |
2025-02-12 |
산둥심시어 바이오파마슈티칼 씨오., 엘티디. |
Bcma, gprc5d 및 t 세포를 표적으로 하는 다중특이적 항체 및 그 응용
|
|
IL317392A
(en)
|
2022-06-07 |
2025-02-01 |
Regeneron Pharma |
Multispecific molecules for modulating T-cell activity and their uses
|
|
EP4536836A1
(en)
|
2022-06-07 |
2025-04-16 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
|
AR129560A1
(es)
|
2022-06-08 |
2024-09-04 |
Tidal Therapeutics Inc |
Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
|
|
KR20250023503A
(ko)
|
2022-06-14 |
2025-02-18 |
아블린쓰 |
T 세포 수용체를 표적화하는 면역글로불린 단일 가변 도메인
|
|
WO2024003873A1
(en)
|
2022-06-30 |
2024-01-04 |
Intrexon Actobiotics Nv D/B/A Precigen Actobio |
Single variable domain antibodies against tumor necrosis factor-alpha
|
|
EP4299125A1
(en)
|
2022-06-30 |
2024-01-03 |
Universite De Montpellier |
Anti-mglur2 biparatopic nanobodies and uses thereof
|
|
EP4299124A1
(en)
|
2022-06-30 |
2024-01-03 |
Universite De Montpellier |
Anti-mglur2 nanobodies for use as biomolecule transporter
|
|
US20250304677A1
(en)
|
2022-07-04 |
2025-10-02 |
Vib Vzw |
Blood-Cerebrospinal Fluid Barrier Crossing Antibodies
|
|
KR102749341B1
(ko)
|
2022-07-08 |
2025-01-06 |
노보 노르디스크 에이/에스 |
FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물
|
|
MA71385A
(fr)
|
2022-07-08 |
2025-04-30 |
Novo Nordisk A/S |
Composés isvd hautement puissants capables de remplacer fviii(a)
|
|
PE20250669A1
(es)
|
2022-07-15 |
2025-03-04 |
Boehringer Ingelheim Int |
Moleculas de union para el tratamiento del cancer
|
|
WO2024017915A1
(en)
|
2022-07-18 |
2024-01-25 |
Ablynx N.V. |
Cx3cr1-binding compounds, uses thereof and related methods
|
|
CA3262611A1
(en)
|
2022-07-22 |
2024-01-25 |
Janssen Biotech, Inc. |
IMPROVED TRANSFER OF GENETIC INSTRUCTIONS TO EFFECTOR IMMUNE CELLS
|
|
WO2024026284A2
(en)
|
2022-07-25 |
2024-02-01 |
Interius Biotherapeutics, Inc. |
Mutated polypeptides, compositions comprising the same, and uses thereof
|
|
AU2023313033A1
(en)
|
2022-07-27 |
2025-03-13 |
Ablynx Nv |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|
|
US20260035434A1
(en)
|
2022-08-01 |
2026-02-05 |
Ose Immunotherapeutics |
Heterodimeric fc-clec-1 fusion molecule and uses thereof
|
|
EP4565610A1
(en)
|
2022-08-02 |
2025-06-11 |
Ose Immunotherapeutics |
Multifunctional molecule directed against cd28
|
|
AU2023320453A1
(en)
|
2022-08-03 |
2025-02-06 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
|
WO2024028476A1
(en)
|
2022-08-05 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of th2-mediated diseases
|
|
WO2024037910A1
(en)
|
2022-08-17 |
2024-02-22 |
Institut National de la Santé et de la Recherche Médicale |
Syk inhibitors for use in the treatment of cancer
|
|
EP4577578A1
(en)
|
2022-08-22 |
2025-07-02 |
Abdera Therapeutics Inc. |
Dll3 binding molecules and uses thereof
|
|
EP4580658A1
(en)
|
2022-08-31 |
2025-07-09 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
|
CN120018862A
(zh)
|
2022-08-31 |
2025-05-16 |
阿雷克森制药公司 |
用于治疗镰状细胞病的融合多肽的剂量和施用
|
|
AU2023334858A1
(en)
|
2022-09-01 |
2025-03-20 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
|
EP4697024A2
(en)
|
2022-09-06 |
2026-02-18 |
Alexion Pharmaceuticals, Inc. |
Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
|
|
EP4584299A2
(en)
|
2022-09-07 |
2025-07-16 |
Quantitative Biosciences, Inc. |
Fentanyl-specific single variable-domain antibodies and use in a continuous agglutination assay
|
|
CN120112550A
(zh)
|
2022-09-09 |
2025-06-06 |
耶鲁大学 |
蛋白水解靶向抗体及其使用方法
|
|
IL319121A
(en)
|
2022-09-15 |
2025-04-01 |
Voyager Therapeutics Inc |
Tau-binding compounds
|
|
WO2024056809A1
(en)
|
2022-09-15 |
2024-03-21 |
Novartis Ag |
Treatment of autoimmune disorders using chimeric antigen receptor therapy
|
|
WO2024068744A1
(en)
|
2022-09-27 |
2024-04-04 |
Vib Vzw |
Antivirals against human parainfluenza virus
|
|
KR20250131767A
(ko)
|
2022-09-28 |
2025-09-03 |
발린크 테라퓨틱스 리미티드 |
다가 단백질 및 스크리닝 방법
|
|
TW202430561A
(zh)
|
2022-09-30 |
2024-08-01 |
法商賽諾菲公司 |
抗cd28抗體
|
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
|
KR20250116642A
(ko)
|
2022-10-28 |
2025-08-01 |
제노 바이오파마 컴퍼니 리미티드 |
새로운 항-ctla4 항체
|
|
WO2024096735A1
(en)
|
2022-10-31 |
2024-05-10 |
Stichting Amsterdam UMC |
Single domain anti-cd169 antibodies
|
|
JP2025537215A
(ja)
|
2022-11-02 |
2025-11-14 |
▲蘇▼州康▲寧▼杰瑞生物科技有限公司 |
Ｇｉｐｒ結合タンパク質及びその使用
|
|
EP4615493A1
(en)
|
2022-11-08 |
2025-09-17 |
Stichting Amsterdam UMC |
Activation inducible antigen receptors for adoptive immunotherapy
|
|
EP4615874A1
(en)
|
2022-11-10 |
2025-09-17 |
Immuvia Inc |
Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
|
|
CN120379763A
(zh)
|
2022-11-15 |
2025-07-25 |
Imec 非营利协会 |
用于液滴操控的方法和系统
|
|
KR20250152696A
(ko)
|
2022-11-21 |
2025-10-23 |
다이안서스 테라퓨틱스 오피씨오, 인코포레이티드. |
C1s에 결합하는 항체 및 이의 용도
|
|
JP2025538642A
(ja)
|
2022-11-29 |
2025-11-28 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
Ｃｌｄｎ１８．２／４－１ｂｂ結合タンパク質及びその医薬的使用
|
|
JP2026500995A
(ja)
|
2022-11-30 |
2026-01-13 |
インテグラル・モレキュラー・インコーポレイテッド |
二重特異性形式を含むクローディン６を対象とする抗体
|
|
WO2024119074A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
|
WO2024123963A2
(en)
|
2022-12-07 |
2024-06-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing monoclonal antibodies against western, eastern, and venezuelan equine encephalitis virus (eev)
|
|
WO2024126363A1
(en)
|
2022-12-12 |
2024-06-20 |
Institut National de la Santé et de la Recherche Médicale |
Image-based high-content screening methods for identifying compounds targeting apicomplexan parasites
|
|
WO2024126805A1
(en)
|
2022-12-15 |
2024-06-20 |
Aarhus Universitet |
Synthetic activation of multimeric transmembrane receptors
|
|
US20260042836A1
(en)
|
2022-12-19 |
2026-02-12 |
Umc Utrecht Holding B.V. |
Btn2a1 binding peptide
|
|
US12195546B2
(en)
|
2022-12-19 |
2025-01-14 |
Sanofi |
CD28/OX40 bispecific antibodies
|
|
JP2026501281A
(ja)
|
2022-12-21 |
2026-01-14 |
ジェンザイム・コーポレーション |
抗ｐｄ－１×４－１ｂｂ結合タンパク質
|
|
EP4638735A1
(en)
|
2022-12-22 |
2025-10-29 |
Biotalys NV |
Methods for genome editing
|
|
WO2024133723A1
(en)
|
2022-12-22 |
2024-06-27 |
Institut National de la Santé et de la Recherche Médicale |
Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
|
|
JP2025542322A
(ja)
|
2022-12-23 |
2025-12-25 |
チマゲン・バイオサイエンシズ，リミテッド |
Ｇｐｒｃ５ｄを標的とする多重特異性ポリペプチド複合物
|
|
AR131494A1
(es)
|
2022-12-23 |
2025-03-26 |
Ablynx Nv |
Vehículos de conjugación a base de proteína
|
|
TW202440159A
(zh)
|
2022-12-29 |
2024-10-16 |
大陸商蘇州創勝醫藥集團有限公司 |
含有治療性抗體的藥物製劑及其用途
|
|
EP4642235A1
(en)
|
2022-12-29 |
2025-11-05 |
Biotalys NV |
Agrochemical compositions
|
|
EP4642233A1
(en)
|
2022-12-30 |
2025-11-05 |
Biotalys NV |
Agglomerate
|
|
WO2024143925A1
(ko)
|
2022-12-30 |
2024-07-04 |
연세대학교 산학협력단 |
Rnase a에 특이적으로 결합하는 항체 또는 펩티드, 및 rnase a 검출 면역분석 장치 및 방법 그리고 rnase a 포집 방법
|
|
EP4642916A2
(en)
|
2022-12-30 |
2025-11-05 |
Biotalys NV |
Secretion signals
|
|
EP4642232A1
(en)
|
2022-12-30 |
2025-11-05 |
Biotalys NV |
Self-emulsifiable concentrate
|
|
AU2024207151A1
(en)
|
2023-01-09 |
2025-06-19 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
KR20250133913A
(ko)
|
2023-01-09 |
2025-09-09 |
베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 |
TGFβ1 결합 분자, GARP-TGFβ1 결합 분자 및 이의 의학적 용도
|
|
IL322053A
(en)
|
2023-01-13 |
2025-09-01 |
Regeneron Pharma |
FGFR3 binding molecules and methods of using them
|
|
TW202434629A
(zh)
|
2023-01-26 |
2024-09-01 |
愛爾蘭商歐薩爾普羅席納有限公司 |
以抗類澱粉β (ABETA)抗體治療神經病症之方法
|
|
EP4655324A1
(en)
|
2023-01-27 |
2025-12-03 |
Vib Vzw |
Cd163-binding conjugates
|
|
WO2024156881A1
(en)
|
2023-01-27 |
2024-08-02 |
Vib Vzw |
CD8b-BINDING POLYPEPTIDES
|
|
WO2024165500A1
(en)
|
2023-02-06 |
2024-08-15 |
Merck Patent Gmbh |
Vhh-based nkp46 binders
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
WO2024165710A1
(en)
|
2023-02-09 |
2024-08-15 |
Seni-Preps B.V. |
Immunoglobulin single variable domains that inhibit urease and use thereof
|
|
IL322575A
(en)
|
2023-02-10 |
2025-10-01 |
Amunix Pharmaceuticals Inc |
Prostate-specific membrane antigen (PSMA)-targeting compositions and methods for their preparation and use
|
|
AU2024221136A1
(en)
|
2023-02-17 |
2025-10-02 |
Ablynx N.V. |
Polypeptides binding to the neonatal fc receptor
|
|
WO2024175031A1
(zh)
|
2023-02-21 |
2024-08-29 |
江苏恒瑞医药股份有限公司 |
Il-36r结合蛋白及其医药用途
|
|
EP4671277A1
(en)
|
2023-02-24 |
2025-12-31 |
Shanghai Mabgen Biotech Ltd. |
Pharmaceutical Composition of the FAP/CD40 Binding Molecule and its Pharmaceutical Use
|
|
WO2024175787A1
(en)
|
2023-02-24 |
2024-08-29 |
Vrije Universiteit Brussel |
Anti-inflammatory pannexin 1 channel inhibitors
|
|
EP4674868A1
(en)
|
2023-03-01 |
2026-01-07 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Fap/4-1bb/cd40 binding molecule and medicinal use thereof
|
|
AR132062A1
(es)
|
2023-03-06 |
2025-05-21 |
Beigene Switzerland Gmbh |
Anticuerpos multiespecíficos anti-cd3 y métodos de uso
|
|
TW202436353A
(zh)
|
2023-03-06 |
2024-09-16 |
瑞士商百濟神州瑞士有限責任公司 |
抗ｃｌｄｎ６與抗ｃｄ３多重特異性抗體以及使用方法
|
|
AR132064A1
(es)
|
2023-03-06 |
2025-05-21 |
Beigene Switzerland Gmbh |
Anticuerpos anti-cldn6 y métodos de uso
|
|
CN120858176A
(zh)
|
2023-03-07 |
2025-10-28 |
居里研究所 |
Brca相关癌症中的ung/udg抑制
|
|
WO2024184479A1
(en)
|
2023-03-08 |
2024-09-12 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of food allergy
|
|
EP4698560A1
(en)
|
2023-03-14 |
2026-02-25 |
Odyssey Therapeutics, Inc. |
Anti-cd25 antigen-binding proteins and uses thereof
|
|
CN121194987A
(zh)
|
2023-03-14 |
2025-12-23 |
奥尔胡斯大学 |
基因改变的nfr5受体激酶
|
|
EP4681729A1
(en)
|
2023-03-15 |
2026-01-21 |
Shanghai Mabgen Biotech Ltd. |
Pharmaceutical composition containing pd-1/pvrig/tigit binding protein and medical use thereof
|
|
WO2024194402A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
|
|
WO2024194401A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Vps4b inhibitor for use in methods for the treatment of hrd cancer
|
|
WO2024194673A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Methods for the treatment of dedifferentiated liposarcoma
|
|
AU2024240821A1
(en)
|
2023-03-23 |
2025-11-06 |
Bodhi Bio Llc |
Compositions and methods for antigen-specific therapy
|
|
WO2024200332A1
(en)
|
2023-03-24 |
2024-10-03 |
Sanofi |
Asthma treatment by blocking il-13 and tslp
|
|
EP4435005A1
(en)
|
2023-03-24 |
2024-09-25 |
Sanofi |
Asthma treatment by blocking il-13 and tslp
|
|
WO2024200846A1
(en)
|
2023-03-30 |
2024-10-03 |
272BIO Limited |
Gnrh-binding polypeptides and uses thereof
|
|
CN121358771A
(zh)
|
2023-04-03 |
2026-01-16 |
非营利性组织佛兰芒综合大学生物技术研究所 |
血-脑屏障穿越抗体
|
|
EP4695290A1
(en)
|
2023-04-13 |
2026-02-18 |
Institut Curie |
Methods for the treatment of t-cell acute lymphoblastic leukemia
|
|
WO2024224323A1
(en)
|
2023-04-24 |
2024-10-31 |
King Abdullah University Of Science Of Technology |
Compositions, systems and methods for multiplex detection of target biomarkers in a sample
|
|
WO2024226829A2
(en)
|
2023-04-26 |
2024-10-31 |
Yale University |
Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
|
|
CN121079319A
(zh)
|
2023-05-08 |
2025-12-05 |
赛诺菲 |
免疫球蛋白单可变结构域的糖基化
|
|
CN121511260A
(zh)
|
2023-05-11 |
2026-02-10 |
非营利性组织佛兰芒综合大学生物技术研究所 |
SLC4A4/NBCe1抑制剂
|
|
WO2024238565A1
(en)
|
2023-05-15 |
2024-11-21 |
Vor Biopharma Inc. |
Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
|
|
KR20260011734A
(ko)
|
2023-05-17 |
2026-01-23 |
오디세이 테라퓨틱스, 인코포레이티드 |
변형된 단일-도메인 항체
|
|
AU2024274792A1
(en)
|
2023-05-23 |
2025-10-23 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
AU2024276787A1
(en)
|
2023-05-23 |
2026-01-15 |
Allygen Group |
Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
|
|
WO2024251826A1
(en)
|
2023-06-05 |
2024-12-12 |
Vib Vzw |
Glyco-engineered antibody-drug-conjugates comprising an oxime linker
|
|
CN121311939A
(zh)
|
2023-06-05 |
2026-01-09 |
赛诺菲 |
使用机器学习模型预测免疫球蛋白单可变结构域的热稳定性
|
|
AU2024286186A1
(en)
|
2023-06-09 |
2026-01-22 |
Merck Patent Gmbh |
Il-18 mimetics
|
|
WO2024251981A1
(en)
|
2023-06-09 |
2024-12-12 |
Umc Utrecht Holding B.V. |
Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
|
|
WO2024256527A1
(en)
|
2023-06-13 |
2024-12-19 |
Institut National de la Santé et de la Recherche Médicale |
Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy
|
|
WO2024259305A1
(en)
|
2023-06-14 |
2024-12-19 |
The Broad Institute, Inc. |
Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
|
|
CN121532425A
(zh)
|
2023-06-22 |
2026-02-13 |
阿布林克斯有限公司 |
靶向pd-l1的免疫球蛋白单可变结构域
|
|
WO2024261235A1
(en)
|
2023-06-22 |
2024-12-26 |
Ablynx Nv |
Chimeric proteins for modulating cytokine receptor activity
|
|
WO2024261344A1
(en)
|
2023-06-23 |
2024-12-26 |
Vib Vzw |
Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
|
|
CN121532423A
(zh)
|
2023-06-29 |
2026-02-13 |
奥德赛治疗股份有限公司 |
抗trailr2抗原结合蛋白及其用途
|
|
EP4483951A1
(en)
|
2023-06-30 |
2025-01-01 |
Université de Liège |
Single-domain antibody for inhibition of neutrophil elastase activity
|
|
US20250034260A1
(en)
|
2023-07-05 |
2025-01-30 |
Sanofi |
Fcrn antagonists for treatment of igg-related diseases and disorders
|
|
AU2024290964A1
(en)
|
2023-07-05 |
2026-01-08 |
CSL Innovation Pty Ltd |
Methods of treating or preventing a complication of sickle cell disease
|
|
TW202509078A
(zh)
|
2023-07-07 |
2025-03-01 |
美商維里迪恩醫療股份有限公司 |
治療慢性甲狀腺眼病之方法
|
|
WO2025024645A1
(en)
|
2023-07-25 |
2025-01-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Rapid method for producing antibodies
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
WO2025032112A1
(en)
|
2023-08-08 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of type 2-mediated diseases
|
|
WO2025032158A1
(en)
|
2023-08-08 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat tauopathies
|
|
WO2025032213A1
(en)
|
2023-08-10 |
2025-02-13 |
Ose Immunotherapeutics |
Identification of hla-dra as a ligand of clec-1 and uses thereof
|
|
WO2025036848A1
(en)
|
2023-08-11 |
2025-02-20 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Anti-muc16 antibodies and uses thereof
|
|
EP4512243A1
(en)
|
2023-08-21 |
2025-02-26 |
Kymab Limited |
Binding molecules
|
|
AR133725A1
(es)
|
2023-09-04 |
2025-10-29 |
Sanofi Sa |
Polipéptidos para uso en el tratamiento de tumores que expresan glipicano-3
|
|
TW202530246A
(zh)
|
2023-09-15 |
2025-08-01 |
愛爾蘭商歐賽爾普羅希那有限公司 |
細胞穿透劑及其用途
|
|
GB202314424D0
(en)
|
2023-09-20 |
2023-11-01 |
Cambridge Entpr Ltd |
A conjugate
|
|
TW202532432A
(zh)
|
2023-09-22 |
2025-08-16 |
比利時商艾伯霖克斯公司 |
二及多價白蛋白結合劑
|
|
WO2025068393A1
(en)
|
2023-09-27 |
2025-04-03 |
Institut Curie |
Methods for the treatment of fibrotic related diseases
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
WO2025073890A1
(en)
|
2023-10-06 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Method to capture circulating tumor extracellular vesicles
|
|
WO2025078418A1
(en)
|
2023-10-10 |
2025-04-17 |
Nano Tag Biotechnologies Gmbh |
Humanized single-domain antibodies binding to epitope tags
|
|
WO2025078401A1
(en)
|
2023-10-11 |
2025-04-17 |
BioNTech SE |
Agents and methods for targeted delivery of immune effector cells
|
|
WO2025078851A1
(en)
|
2023-10-11 |
2025-04-17 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods of treating cognitive deficit
|
|
NL2036011B1
(en)
|
2023-10-12 |
2025-04-30 |
Synapse Res Institute |
Molecules for reversing anti-coagulant activity of direct oral anticoagulants
|
|
TW202515903A
(zh)
|
2023-10-12 |
2025-04-16 |
瑞士商百濟神州瑞士有限責任公司 |
手術前後基於抗ｐｄ－１之治療
|
|
WO2025080751A2
(en)
|
2023-10-13 |
2025-04-17 |
Odyssey Therapeutics, Inc. |
Anti-cdh17 antigen-binding proteins and uses thereof
|
|
WO2025093541A1
(en)
|
2023-10-31 |
2025-05-08 |
Ose Immunotherapeutics |
Combination of interleukin 7 and tumour associated antigen vaccine
|
|
WO2025093683A1
(en)
|
2023-11-03 |
2025-05-08 |
Neuvasq Biotechnologies Sa |
Wnt7 signaling agonists
|
|
TW202540169A
(zh)
|
2023-11-08 |
2025-10-16 |
法商賽諾菲公司 |
基於ｃｄ２５的溶酶體降解物及其用途
|
|
WO2025109176A1
(en)
|
2023-11-22 |
2025-05-30 |
Exevir Bio Bv |
Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
|
|
AR134512A1
(es)
|
2023-12-01 |
2026-01-21 |
Ablynx Nv |
Polipéptidos activados con precisión
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025125577A1
(en)
|
2023-12-14 |
2025-06-19 |
Vib Vzw |
Antibodies against influenza b virus
|
|
WO2025136985A1
(en)
|
2023-12-17 |
2025-06-26 |
Viridian Therapeutics, Inc. |
Compositions, doses, and methods for treatment of thyroid eye disease
|
|
WO2025132833A1
(en)
|
2023-12-20 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Anti trypsin-3 single domain antibody
|
|
WO2025133253A2
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Protein-based conjugation carriers for intranuclear delivery
|
|
WO2025133390A1
(en)
|
2023-12-22 |
2025-06-26 |
Biotalys NV |
Anti-fungal vhh antibodies
|
|
WO2025133252A1
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Immunoglobulin single variable domains targeting ceacam5
|
|
WO2025133166A1
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Protein-based carriers for site-specific amine conjugation
|
|
WO2025151502A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Modified antibodies
|
|
WO2025151496A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2025151492A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2025154056A1
(en)
|
2024-01-21 |
2025-07-24 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Anti-insect cda nanobodies and uses thereof
|
|
WO2025154058A1
(en)
|
2024-01-21 |
2025-07-24 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Anti-insect hsp70 nanobodies and uses thereof
|
|
WO2025160546A1
(en)
|
2024-01-26 |
2025-07-31 |
The Johns Hopkins University |
Dendrimer conjugate compositions for intracellular delivery of antibodies and antibody fragments
|
|
WO2025162980A1
(en)
|
2024-01-30 |
2025-08-07 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of breast cancer using a jnk-1 inhibitor
|
|
AU2024427245A1
(en)
|
2024-02-05 |
2026-01-22 |
Regenecore Biotech Co., Ltd |
Anti-cd33 single-domain antibody, anti-cd123 antibody, polypeptide targeting cd33 and cd123 molecules, and use thereof
|
|
WO2025168716A1
(en)
|
2024-02-07 |
2025-08-14 |
Eyebiotech Limited |
Compositions, doses, and methods for treatment of ocular diseases
|
|
TW202543581A
(zh)
|
2024-02-12 |
2025-11-16 |
美商艾伊拉醫療公司 |
遞送組成物
|
|
WO2025178959A1
(en)
|
2024-02-20 |
2025-08-28 |
University Of Georgia Research Foundation, Inc. |
Single-domain antibodies and variants thereof against tab1
|
|
WO2025176777A1
(en)
|
2024-02-20 |
2025-08-28 |
Institut Curie |
Dut inhibition in homologous recombination deficiency cancer
|
|
WO2025181155A1
(en)
|
2024-02-26 |
2025-09-04 |
Vib Vzw |
Human beta-glucocerebrosidase binders and uses thereof
|
|
US20250361320A1
(en)
|
2024-02-27 |
2025-11-27 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
TW202539744A
(zh)
|
2024-02-27 |
2025-10-16 |
美商必治妥美雅史谷比公司 |
抗ｃｅａｃａｍ５抗體藥物軛合物
|
|
WO2025191018A1
(en)
|
2024-03-13 |
2025-09-18 |
Institut National de la Santé et de la Recherche Médicale |
Mrgpre binding agent for use in the treatment of inflammatory and pain disorders
|
|
WO2025196308A1
(en)
|
2024-03-22 |
2025-09-25 |
Vib Vzw |
Means and methods for displaying fc-containing proteins on cells and selection thereof
|
|
WO2025207946A1
(en)
|
2024-03-28 |
2025-10-02 |
Genzyme Corporation |
Polypeptides binding to a specific epitope of the transferrin receptor 1
|
|
WO2025212726A2
(en)
|
2024-04-04 |
2025-10-09 |
Compass Therapeutics, Inc. |
Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2025219231A1
(en)
|
2024-04-15 |
2025-10-23 |
Vib Vzw |
Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
|
|
WO2025224050A1
(en)
|
2024-04-22 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treatment of patients suffering from hypomelanosis of ito
|
|
WO2025226603A1
(en)
|
2024-04-22 |
2025-10-30 |
Surface Oncology, LLC |
Methods for treating cancer using anti-ccr8 antibodies
|
|
WO2025224297A1
(en)
|
2024-04-26 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to tgfbi and uses thereof
|
|
WO2025231143A1
(en)
|
2024-04-30 |
2025-11-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies against ev-d68
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2025238157A1
(en)
|
2024-05-15 |
2025-11-20 |
Katholieke Universiteit Leuven |
Multispecific binding agent suitable for use in cancer immune therapy
|
|
WO2025242836A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
|
|
WO2025242835A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of cancer
|
|
WO2025245381A1
(en)
|
2024-05-23 |
2025-11-27 |
The Trustrees Of Dartmouth College |
Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
|
|
WO2025255558A2
(en)
|
2024-06-07 |
2025-12-11 |
Odyssey Therapeutics, Inc. |
Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
|
|
WO2025255435A2
(en)
|
2024-06-07 |
2025-12-11 |
Odyssey Therapeutics, Inc. |
Antigen-binding proteins against serum albumin and uses thereof
|
|
WO2025257408A1
(en)
|
2024-06-14 |
2025-12-18 |
Sanofi |
Treatment of solid organ transplant subjects with cd28/ox40 bispecific antibodies
|
|
WO2025264860A2
(en)
|
2024-06-18 |
2025-12-26 |
Yale University |
Methods of treating post-covid airway disease
|
|
US20260007757A1
(en)
|
2024-06-18 |
2026-01-08 |
Ablynx Nv |
Antibody-recruiting molecules
|
|
WO2026002934A1
(en)
|
2024-06-25 |
2026-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Combination of a slc16a1 inhibitor and a smad3 inhibitor for treating cancer
|
|
WO2026006708A2
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Anti-cd25 antigen-binding proteins and uses thereof
|
|
WO2026006809A1
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Multispecific molecules binding tnfr2 and cd25 and uses thereof
|
|
WO2026003239A2
(en)
|
2024-06-28 |
2026-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Method to improve macrophages functions
|
|
WO2026008665A1
(en)
|
2024-07-01 |
2026-01-08 |
Vib Vzw |
Binders of the pd-1•pd-l1 complex and their use
|
|
WO2026011013A1
(en)
|
2024-07-02 |
2026-01-08 |
Epibiologics, Inc. |
Binding agents and uses thereof
|
|
WO2026008785A1
(en)
|
2024-07-03 |
2026-01-08 |
Biotalys NV |
Agrochemical compositions
|
|
WO2026013153A1
(en)
|
2024-07-10 |
2026-01-15 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from myc-high tumors
|
|
WO2026024863A2
(en)
|
2024-07-24 |
2026-01-29 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists
|
|
WO2026030375A2
(en)
|
2024-07-30 |
2026-02-05 |
Genzyme Corporation |
Lipid nanoparticles and methods of manufacture and use thereof
|
|
WO2026027659A1
(en)
|
2024-07-31 |
2026-02-05 |
Seni-Preps B.V. |
Improved immunoglobulin single variable domains that inhibit urease and use thereof
|
|
WO2026036047A1
(en)
|
2024-08-08 |
2026-02-12 |
Altus Enterprises, Inc. |
Antibody molecules to fixa and fx and uses thereof
|